AU2020257379B2 - FXR small molecule agonist and preparation method therefor and use thereof - Google Patents
FXR small molecule agonist and preparation method therefor and use thereof Download PDFInfo
- Publication number
- AU2020257379B2 AU2020257379B2 AU2020257379A AU2020257379A AU2020257379B2 AU 2020257379 B2 AU2020257379 B2 AU 2020257379B2 AU 2020257379 A AU2020257379 A AU 2020257379A AU 2020257379 A AU2020257379 A AU 2020257379A AU 2020257379 B2 AU2020257379 B2 AU 2020257379B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- control group
- compound represented
- general formula
- lxf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000000556 agonist Substances 0.000 title abstract description 5
- 150000003384 small molecules Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 220
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 210000004185 liver Anatomy 0.000 claims description 32
- -1 benzaldehyde compound Chemical class 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 16
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 210000005228 liver tissue Anatomy 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 7
- 239000003613 bile acid Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 229960002591 hydroxyproline Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- OAKURXIZZOAYBC-UHFFFAOYSA-N 3-oxopropanoic acid Chemical compound OC(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-N 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 208000001130 gallstones Diseases 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 108010082126 Alanine transaminase Proteins 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108090000340 Transaminases Proteins 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 102000014898 transaminase activity proteins Human genes 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 106
- 239000007787 solid Substances 0.000 description 96
- 238000005481 NMR spectroscopy Methods 0.000 description 88
- 239000002994 raw material Substances 0.000 description 86
- 238000001308 synthesis method Methods 0.000 description 84
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 72
- 229940125904 compound 1 Drugs 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 37
- 102100038495 Bile acid receptor Human genes 0.000 description 29
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 29
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 29
- 102100027981 Septin-7 Human genes 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 229920000728 polyester Polymers 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102100027935 Attractin-like protein 1 Human genes 0.000 description 8
- 206010019668 Hepatic fibrosis Diseases 0.000 description 8
- 239000003513 alkali Substances 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000007875 V-40 Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 102000006255 nuclear receptors Human genes 0.000 description 5
- 108020004017 nuclear receptors Proteins 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- CGVFRZMQURRQIE-UHFFFAOYSA-N COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 Chemical compound COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 CGVFRZMQURRQIE-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- YYMCYJLIYNNOMK-MEKDEQNOSA-N (1r,5s)-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1C(O)C[C@@H]2CC[C@H]1N2 YYMCYJLIYNNOMK-MEKDEQNOSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- YYMCYJLIYNNOMK-UHFFFAOYSA-N N-normethyltropine Natural products C1C(O)CC2CCC1N2 YYMCYJLIYNNOMK-UHFFFAOYSA-N 0.000 description 2
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 108010003814 member 2 group B nuclear receptor subfamily 0 Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- ZGZMERZZMMOKJK-UHFFFAOYSA-N 3-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-N'-hydroxybenzenecarboximidamide Chemical compound C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4CCN(CC4)C5=CC=CC(=C5)/C(=N/O)/N ZGZMERZZMMOKJK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940122206 Farnesoid X receptor antagonist Drugs 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 description 1
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 description 1
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108010023795 VLDL receptor Proteins 0.000 description 1
- 101710177612 Very low-density lipoprotein receptor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- WIVXEZIMDUGYRW-UHFFFAOYSA-L copper(i) sulfate Chemical compound [Cu+].[Cu+].[O-]S([O-])(=O)=O WIVXEZIMDUGYRW-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CDHICTNQMQYRSM-UHFFFAOYSA-N di(propan-2-yl)alumane Chemical compound CC(C)[AlH]C(C)C CDHICTNQMQYRSM-UHFFFAOYSA-N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 1
- WRGLZAJBHUOPFO-UHFFFAOYSA-N methyl 3-oxo-3-phenylpropanoate Chemical compound COC(=O)CC(=O)C1=CC=CC=C1 WRGLZAJBHUOPFO-UHFFFAOYSA-N 0.000 description 1
- HNNFDXWDCFCVDM-UHFFFAOYSA-N methyl 4-methyl-3-oxopentanoate Chemical compound COC(=O)CC(=O)C(C)C HNNFDXWDCFCVDM-UHFFFAOYSA-N 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.
Description
Technical field The present invention relates to the field of medicine, and relates to a class of compounds as FXR agonist and preparation therefor and use thereof. Specifically, it relates to a class of non-steroidal compounds that can be used as FXR agonist and the enantiomer, diastereomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof, the preparation method therefor and use thereof in the manufacture of a medicament for the treatment of FXR-related disease.
Background technique Nuclear receptors are widely present in organisms and are a type of nuclear transcription regulators that rely on specific ligand activation. Metabolic nuclear receptors are a type of nuclear receptors that regulate substance metabolism, cell proliferation, and apoptosis in the body. Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily, which was first discovered by Foman et al. in 1995 and named because its transcriptional activity can be enhanced by farnesoid. The FXR structure contains ligand-independent transcription activation function domain (AF1) at amino-terminal, DNA binding domain (DBD), hinge region, ligand binding domain (LBD) and ligand-dependent transcription activation function domain (AF2) at carbon terminal, which is a typical nuclear receptor structure. FXR is activated by bile acids in the body and participates in the processes of bile acid metabolism, lipid metabolism, and sugar metabolism in the living body. The mechanism by which FXR regulates bile acid metabolism and transport is mainly accomplished by regulating the transcription of cholesterol 7a hydroxylase (CYP7A1) which is a rate-limiting enzyme of bile acid synthesis. Although FXR cannot directly act on the CYP7Al promoter, it can induce the expression of small heterodimer partner (SHP) and combine HNF-4a (hepatocyte nuclear factor 4a) and LRH-1 (liver receptor homolog) to down-regulate the transcription of CYP7A1. In the process of lipid metabolism, FXR in the liver regulates lipid metabolism and transport to reduce plasma free fatty acids and triglycerides by directly or indirectly regulating PPARa, VLDL receptor (very low density lipoprotein receptor, VLDLR), proprotein convertase subtilisin kexin type 9 (PCSK9), scavenger receptor group B type 1 (SRB1), phosphor lipid transfer protein (PLTP), liver X receptor (LXR), sterol regulatory element-binding protein-IC (SREBP-1C) and fatty acid synthetase (FAS), and activating lipoprotein lipase (LPL) and the like. In the process of glucose metabolism, the activation of FXR can promote liver glycogen synthesis and increase insulin sensitivity and insulin secretion to control blood glucose levels in the body. Since FXR plays an important role in the processes of bile acid metabolism, lipid metabolism and glucose metabolism, FXR ligand small molecule compounds are expected to be used as new medicament for the treatment of hypertriglyceridemia, type 2 diabetes, metabolic syndrome, NAFLD and other metabolic-related diseases.
Summary of the invention The present invention seeks to provide a FXR small molecule agonist and preparation method therefor and use thereof.
In the first aspect of the present invention, it provides a compound represented by general formula I, or enantiomer, diastereomer, tautomer, racemate, solvate, prodrug or pharmaceutically acceptable salt thereof,
0 R2 N H O A N
R11 N-'
R 12 R13
wherein, R11 , R 12 , R1 3 , R 14 and R1 5 are each independently hydrogen, halogen, halogenated C1-6 alkyl, halogenated C-C6 alkoxy, C-C6 alkyl, C1-6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, cyano or nitro; R2 is C6-C12 aryl, C1-C6 alkyl or C3-C6 cycloalkyl; Q is a 4-8 membered heterocyclyl; A is the following substituted or unsubstituted group: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, and the "substituted" means that there is one, two or three substituents selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1-6 alkyl, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkoxy; X is O or S. In another preferred example, R 1 , R 12 , R 13 , R 14 and R 1 5 are each independently hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, or trifluoromethoxy. In another preferred example, R 1 2 , R 13 and R 14 are hydrogen. In another preferred example, R1 1 and R1 5 are each independently hydrogen, chlorine, bromine, trifluoromethyl, or trifluoromethoxy. In another preferred example, R 2 is phenyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl or cyclopentyl. In another preferred example, Q is a 4-8 membered nitrogen-containing heterocyclyl or a 4-7 membered nitrogen-containing heterocyclyl.
In another preferred example, Q is , ' , , or
In another preferred example, A is the following substituted or unsubstituted group: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, and the "substituted" means that there is one or two substituents selected from the group consisting of fluorine, chlorine, bromine, Ci-C4 alkyl, C3-C6 cycloalkyl, Ci-C4 alkoxy, and C3-C6 cycloalkoxy. In another preferred example, A is the following substituted or unsubstituted group: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, and preferably, A is the following substituted or unsubstituted group: phenyl, pyridyl, indolyl, and the "substituted" means that there is one or two substituents selected from the group consisting of fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, methyl, ethyl and propyl. In the present invention, when there are two or more substituents, each substituent is the same or different. F F N N F
In another preferred example, A is / , /, , or F
In another preferred example, the pharmaceutically acceptable salt in the present invention refers to a salt formed from inorganic acid such as phosphoric acid, sulfuric acid, hydrochloric acid, etc., or from organic acid such as acetic acid, tartaric acid, citric acid, malic acid, etc., or from acidic amino acid such as aspartic acid, glutamic acid, etc.; or a salt formed from inorganic base, such as sodium, potassium, calcium, aluminum and ammonium salts. In another preferred example, the compound is:
N\ 0 NHN NH NO NN ONN N N N O
-3 12 3
N- 0 NN 0.,- -- /
0-0 H -H N I C 4 /\/-O 0 6 5 o 0 p0 NIP, NN N N N- ,N0 0 (NIN Ni cl N CF 3 /N OCF3 '0
7 ~89
00
N~o N-'(0 HN-k Il HN 00 0 f 1314 15
F0 NN N O-N - N~ N N Ci CI /i ,l o ci ci N~ HN4 NN NN 0 0 1
13 17 18
N N~ N
NI0 19l 20 c 21l0 l
0N F C F
0\ 0~ 0~N N N F3 \ NH N \/ N0 3CF N '
/ N -ON N 0 C N, N N C3 ''0 ocl N 0' F N- NOC 3 HN~ N1CF
259 260 2
0 N0~ 0 F N \0 N ~~N \ N CF 3 / N'' CF 3 / 0 NCF3 HN-I~, HN-lJ I 280 29 0 F N4
N N NN, N.N- '--. N N~ NN HN OCF HN4 HN 31 F 0 -2 0 273 0
0 F 0 O-4-
OCF 3 N 'O F F N N'N
34 H HN0' 36N,
N CF N NO OCF N OCFN NO 3- HN 0 38 N OHN4
40 4 H0 or 42 H
The compound of the present invention has an asymmetric center, achiral axis, and a -a-A ON - N' N chiral plane, and can exist in the form of racemate, R-isomer, or S-isomer. Those skilled in the o 0 art can use conventional technical means to obtain R-isomer and/or S-isomer from racemate resolution.
In the second aspect of the present invention, it providesa method for preparing the compound according to the first aspect, which includes the following steps: R2 R22
CN a N'H b N N Q A N R -Q ,N
' R2 R40 R 1 RN O r 11 x
R 13 R 13 1
(a')reactinga compound represented by generalformulaVII with hydroxylamine hydrochloride toproducea compound represented by generalnformula VIII; (b') reactingthecompoundrepresentedbythegeneralformulaVIIIundertheactionof phosgene, triphosgene, carbonyldiimidazole or thiocarbonyldiimidazole to produce the compound represented bythe general formulaI, wherein, the definitions of X,R 2 , Q,A, R 1 ,R 1 2 , R 1 3 , R1 4 and RISare described as above. In another preferred example, the compound represented by general formula VII is prepared by o ingtes the following steps:
OH O R2 0 /0 NN COOMe N Br R R 15 R" R 15 b R R 15 C 21 4 a R12 R 12 R 14 R 124 R 14 R" R15 RR1R1 R12 R14
|| ||| IV V
R2 R20
\ o CN
d R 11 R 15 e
R 12 R4 R 13 13 R Vil VI
a) reacting substituted benzaldehyde compound represented by general formula II as starting materials with hydroxylamine hydrochloride to obtain an intermediate and then chlorinating the intermediate with N-chlorosuccinimide (NCS) to produce a compound represented by general formula III; b) reacting the compound represented by the general formula III with 3-oxopropionate to obtain a compound represented by the general formula IV; c) reducing the ester in the compound represented by formula IV to produce alcohol, and then brominating to produce a compound represented by V; d) reacting the compound represented by general formula V with Q-OH to produce a compound represented by general formula VI; e) coupling the compound represented by general formula VI with Br-A-CN under the catalysis of copper or palladium to obtain the compound represented by general formula VII, in each formula, the definitions of R2 , Q, A, R, R1 2 , R1 3 , R 14 and R1 5 are described as above. In another preferred example, the compound represented by general formula VII is prepared by the following steps: R2 R2 O
N Br N O ACN f HO-Q-R111 R11 OH + F,ACN t H-AC +1 'CN Q Ar + 14 R1 R13R R1 R" IX R V VII
f) reacting Q-OH with F-A-CN to generate a compound represented by general formula IX; g) reacting a compound represented by the general formula V with the compound represented by the general formula IX to produce the compound represented by the general formula VII, in each formula, R2 , Q, A, R", R 12 , R1 3 , R 14 and R" are defined as above.
In the third aspect of the present invention, it provides a pharmaceutical composition, comprising: the compound represented by the general formula I according to the first aspect, or the enantiomer, diastereomer, tautomer, racemate, solvate, prodrug, or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The compound provided by the present invention can be used alone or mixed with pharmaceutically acceptable auxiliary material (such as excipient, diluent, etc.) to prepare tablet, capsule, granule or syrup for oral administration. The pharmaceutical composition can be prepared according to conventional methods in pharmacy.
In the fourth aspect of the present invention, it provides use of the compound represented by the general formula I according to the first aspect, or the enantiomer, diastereomer, tautomer, racemate, solvate, prodrug, or pharmaceutically acceptable salt thereof, (a) as an FXR agonist; (b) for the manufacture of a medicament for the treatment of FXR-related diseases; (c) to reduce the levels of ALP, ALT, AST and TBA in serum; (d) to reduce the amount of hydroxyproline in liver tissue; (e) to down-regulate the expression of a-SMA and Collal mRNA in liver tissue; or (f) to reduce the content of collagen in the liver. In another preferred example, the FXR-related disease is a disease related to bile acid metabolism, carbohydrate metabolism, lipid metabolism, inflammation, and/or liver fibrosis. In another preferred example, the FXR-related disease is non-alcoholic fatty liver (NASH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), gallstone, non-alcoholic liver cirrhosis, liver fibrosis, cholestatic liver disease, hyperlipidemia, hypercholesterolemia, or diabetes.
It should be understood that, within the scope of the present invention, each of the above technical features of the present invention and each of the technical features specifically described below (e.g., examples) can be combined with each other, thereby forming a new or preferred technical solution. Each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equal or similar purpose. Due to space limitations, they will not be redundantly described herein.
Brief description of the drawings Figure 1 shows the effect of compound 1 administered for 4 weeks on ALP in serum, hydroxyproline in liver, a-SMA and Collal mRNA in liver, *P<0.05, **P<0.01, ***P<0.001, compared with the model control group (vehicle group). Figure 2 shows the effect of compound 1 administered for 4 weeks on the content of collagen in liver pathological section. Figure 3 shows the effect of compound 8 administered for 3 and 6 weeks on ALT, AST, TBA, and LDH levels in serum, *P<0.05, **P<0.01, ***P<0.001, compared with the model control group (vehicle group). Figure 4 shows the effect of compound 8 administered for 6 weeks on the expression of a-SMA and Collal mRNA in the liver, *P<0.05, **P<0.01, ***P<0.001, compared with the model control group (vehicle group). Figure 5 shows the effect of compound 8 administered for 4 weeks on the content of collagen in liver pathological section, *P<0.05, **P<0.01, ***P<0.001, compared with the model control group (vehicle group).
Detailed description After extensive and intensive researches, the inventors of the present application developed a class of non-steroidal compounds that can be used as FXR agonist, which have the ability to agonize FXR at the molecular and cellular levels. Studies have shown that the compounds of the present application can reduce ALP, ALT, AST, and TBA levels in serum, reduce the amount of hydroxyproline in the liver tissue, down-regulate the expression of a SMA and Collal mRNA in the liver tissue, and reduce the content of collagen in the liver. The compound of the present invention has the advantages of high FXR agonistic activity, simple synthesis, easy availability of raw materials, etc., and can be used for the manufacture of a medicament for treating FXR-related diseases. On this basis, the present invention has been completed.
Terms In the present invention, the halogen is F, Cl, Br or I. In the present invention, unless otherwise specified, the terms used have the general meanings known to those skilled in the art. In the present invention, the term "Ci-C" refers to 1, 2, 3, 4, 5 or 6 carbon atoms, and "Ci-Cs" refers to 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, and so on. "3-10 membered" refers to 3 10 ring atoms, and so on. In the present invention, the term "alkyl" refers to a saturated linear or branched hydrocarbon moiety. For example, the term "Ci-C6alkyl" refers to a straight or branched chain alkyl having 1 to 6 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl, etc.; preferably ethyl, n propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. In the present invention, the term "alkoxy" means -O-(Ci-C6 alkyl) group. For example, the term "Ci-C6alkoxy" refers to a straight or branched chain alkoxy having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, n-propoxy, isopropoxy, butoxy and so on. In the present invention, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon moiety, for example, the term "C3-Ciocycloalkyl" refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and the like. The terms "C3-C cycloalkyl", "C3-C7 cycloalkyl" and "C3-C6 cycloalkyl" have similar meanings. In the present invention, the term "cycloalkoxy" means cycloalkyl-O-, and cycloalkyl is described as above. In the present invention, the term "4-7 membered nitrogen-containing heterocyclyl" refers to a cycloalkyl ring having 3-7 ring atoms and containing 1, 2 or 3 N atoms, and includes, but not limited to, azacyclopentane ring, azacyclohexane ring, azacycloheptane ring and the like. In the present invention, the term "aryl" means a hydrocarbyl moiety containing one or more aromatic rings. For example, the term "C6-C12 aryl" refers to an aromatic ring group with 6 to 12 carbon atoms that does not contain heteroatoms in the ring, such as phenyl, naphthyl and the like. The term "C6-Cio aryl" has a similar meaning. Examples of aryl include, but are not limited to, phenyl (Ph), naphthyl, pyrenyl, anthracenyl, and phenanthryl. In the present invention, the term "heteroaryl" means a moiety containing one or more aromatic rings with at least one heteroatom (such as N, 0 or S), for example, the term "3-12 membered heterocyclyl" means a saturated or unsaturated 3-12 membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen on the ring, such as dioxolyl and the like. The term "3-7 membered heterocyclyl" has a similar meaning. Examples of heteroaryl groups include furyl, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl, quinolinyl, isoquinolinyl, and indolyl. In the present invention, the term "heterocyclyl" means a cyclic group containing at least one ring heteroatom (such as N, 0 or S), such as furyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, pyrimidinyl, tetrahydropyridyl, pyrrolinyl, dihydropyridyl, dihydrofuranyl, dihydrothienyl, pyranyl. Unless otherwise specified, the alkyl, alkoxy, cycloalkyl, heterocyclyl, and aryl described herein are substituted and unsubstituted groups. Possible substituents on alkyl, alkoxy, cycloalkyl, heterocyclyl and aryl include, but are not limited to: hydroxyl, amino, nitro, cyano, halogen, C1-C6 alkyl, C2-Cio alkenyl, C2-Cio alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, Ci-C2o heterocycloalkyl, Ci-C2o heterocycloalkenyl, Ci-C6 alkoxy, aryl, heteroaryl, heteroaryloxy, Ci-Cio alkylamino, Ci-C2o dialkylamino, arylamino, diarylamino, Ci-Cio alkylsulfamoyl, arylsulfamoyl, Ci-Cio alkylimino, Ci-Cio alkylsulfoimino, arylsulfoimino, mercapto, Ci-Cio alkylthio, Ci-Cio alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, guanidinyl, ureido, cyano, acyl, thioacyl, acyloxy, carboxyl and carboxylate group. On the other hand, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl may also be fused to each other. In the present invention, the substitution is mono-substitution or poly-substitution, and the poly-substitution is di-substitution, tri-substitution, tetra-substitution, or penta substitution. The di-substitution means that there are two substituents, and so on. The pharmaceutically acceptable salt of the present invention may be a salt formed by an anion and a positively charged group on the compound of formula I. Suitable anion is chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate, glutamate, glucuronate, lactate, glutarate or maleate ion. Similarly, a salt can be formed from a cation and a negatively charged group on the compound of formula I. Suitable cation includes sodium ion, potassium ion, magnesium ion, calcium ion and ammonium ion, such as tetramethylammonium ion. In another preferred example, "pharmaceutically acceptable salt" refers to a salt formed by a compound of formula I and an acid selected from the group consisting of hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, nitric acid, methanesulfonic acid, acid, aminosulfonic acid, salicylic trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalic acid, pyruvic acid, malic acid, glutamic acid, p toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid, etc.; or sodium salt, potassium salt, calcium salt, aluminum salt or ammonium salt formed by a compound of formula I and inorganic base; or methylamine salt, ethylamine salt or ethanolamine salt formed by a compound of general formula I and organic base.
Preparation method The preparation method of the compound represented by the general formula I of the present invention, the synthetic route is as follows:
OH O R2 0 N C1 N \ COOMe O N Br 15 15 R R R R b R R 15 C a -- R1 R15
12 / R112' R14 R 124 R14R 1 R3RRR13 R12 R RR
|| ||| IV V
R0 R2 R2 2 O N O-Q N 'CN ,~ OQA N
d R11 R15 e R11 R15 R1 R15 H2 N
R12 R14 R12 R14 R12 R14
R 13 R13 R13 VI VII Vill
R2 0 O O-Q-A
R1 R 15 HN
R12 R14 R13
The preparation method includes the following steps: a) reacting substituted benzaldehyde as a starting material with hydroxylamine hydrochloride under the action of an alkali to obtain an intermediate and then chlorinating with N-chlorosuccinimide (NCS) to form a compound represented by the general formula III; b) reacting the compound represented by the general formula III with the corresponding 3-oxopropionate under an alkali condition to form a compound represented by the general formula IV; c) reducing the ester in the compound represented by the general formula IV by a reducing agent to generate the corresponding alcohol, and then brominating to form the compound represented by V, d) reacting the compound represented by the general formula V with Q-OH under the action of an alkali to form the compound represented by the general formula VI; e) coupling the compound represented by the general formula VI with Br-A-CN under the catalysis of copper or palladium to obtain a cyano compound represented by the general formula VII; a') reacting the compound represented by the general formula VII with hydroxylamine hydrochloride under the action of an alkali to produce a compound represented by the general formula VIII; b') reacting the compound represented by the general formula VIII under the action of phosgene, triphosgene, carbonyldiimidazole or thiocarbonyldiimidazole to produce the compound represented by the general formula I. R2 0 N O-Q-A .C CN 11 f g R R OH + FsA'CN : HO-Q-A'CN V R12 R4 Ix R 13 VIl
The cyano compound represented by the general formula VII can also be prepared by the above route, including the following steps: f) substituting the fluorine in F-A-CN with the amino in Q-OH under the action of an alkali to generate compound IX; g) directly reacting a compound represented by the general formula V with the prepared IX under the action of an alkali to form the compound represented by the general formula VI; wherein, R 2, R, R 1 2, R 13 , R 14 , R 1,5 Q, A ring and X are defined as above. The alkali in steps a), b), d), a'), f) and g) is selected from triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, 1,8-diazabicycloundec-7-ene, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide, sodium tert-butoxide, butyl lithium, lithium diisopropylamide. The alkali in step b) is selected from the group consisting of triethylamine, diisopropylethylamine, pyridine, DBU, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, and potassium ethoxide. The reducing agent in step c) is selected from the group consisting of sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, lithium aluminum hydride, diisopropyl aluminum hydride, and borane. The copper catalyst in step e) is cuprous iodide, cuprous oxide, and cuprous sulfate; the palladium catalyst is palladium acetate, tetrakis(triphenylphosphine) palladium, bis(acetonitrile) palladium (II) chloride, dichloride palladium, tris(dibenzylideneacetone)dipalladium, bistriphenylphosphorus palladium dichloride, tris(dibenzylideneacetone)dipalladium-chloroform adduct, 1,1'-bis(diphenylphosphino) ferrocene palladium(II) dichloride.
Pharmaceutical composition The present invention also provides a pharmaceutical composition, which contains active ingredient in a safe and effective amount, and a pharmaceutically acceptable carrier. The "active ingredient" in the present invention refers to the compound of formula I in the present invention. The "active ingredient" and pharmaceutical composition of the present invention are used in the manufacture of a medicament for treating FXR-related diseases. The "active ingredient" and pharmaceutical composition of the present invention can be used as FXR agonist. In another preferred example, it is used in the manufacture of a medicament for preventing and/treating a disease regulated by FXR agonist. "Safe and effective amount" means that the amount of the active ingredient is sufficient to significantly improve the condition without causing serious side effects. Generally, the pharmaceutical composition contains 1-2000 mg of active ingredient/dose, more preferably, 10-200 mg of active ingredient/dose. Preferably, the "one dose" is a tablet. "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and sufficiently low toxicity. "Compatibility" herein means that each component in the composition can be blended with each other and can be blended with the active ingredient of the present invention without significantly reducing the efficacy of the active ingredient. Examples of pharmaceutically acceptable carriers include cellulose and derivatives thereof (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricant (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier (such as Tween*), Wetting agent (such as sodium lauryl sulfate), coloring agent, flavoring agent, stabilizer, antioxidant, preservative, pyrogen-free water and the like. The administration method of the active ingredient or the pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but are not limited to): oral administration, intratumoral administration, rectal administration, parenteral (intravenous, intramuscular, or subcutaneous) administration and the like. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances. In addition to these inert diluents, the composition may also contain adjuvants such as wetting agents, emulsifying agents and suspending agents, sweetening agents, flavoring agents and perfumes. In addition to the active ingredient, the suspension may contain suspending agent, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitan ester, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like. The composition for parenteral injection may contain physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non aqueous carriers, diluents, solvents or excipients include water, ethanol, polyol and suitable mixtures thereof. The compound of the present invention can be administered alone or in combination with other therapeutic drugs (such as hypolipidemic drugs). When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is administered to the mammal (such as a human) in need of treatment, wherein the dosage at which the drug is administered is the pharmaceutically effective administration dosage. For a person of 60kg body weight, the daily dose is usually 1-2000 mg, and 20-500 mg is preferred. Centainly, the specific dosage should be determined by considering factors such as the route of administration, the patient's health status, etc., which are within the skill range of a skilled physician.
The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental methods without specific conditions in the following examples generally follow the conventional conditions (eg. the conditions described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989)) or the conditions recommended by the manufacturer. Unless stated otherwise, percentages and parts are percentages by weight and parts by weight.
Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to the skilled in the art. In addition, any methods and materials similar to or equivalent to those described can be applied to the method of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only. The instruments and main experimental materials used are as follows. The reagents and anhydrous solvents used were purchased from Chinese commercial companies. Unless otherwise specified, they were used directly. 1 H and 1 3 C NMR were measured by BrukerAM-400 and Varian Mercury plus-400 nuclear magnetic resonance instruments, and mass spectrometry was measured by Agilent 6230 mass spectrometer and 200- 300 mesh of column chromatography silica gel (Qingdao Ocean Chemical Factory), HSGF254 TLC plate (Yantai Chemical Industry Research Institute).
Route 1
OH O R2 0 / \0 N CI COOMe Br R15 R R 15 b R R 15 C 21a R" R15 R 12 R 12 R 14 R 124 R 1 2 R13 R1 R"4 R131R
11 111 IV V
0 R2 0 R2 R2 0-/ O..Q-A a' / O.QAN O
15 N d e15QR11 R R H2
R1 2 l R4 R 12 / Ri4 R 12 / Ri4
R 13 R13 R13 Vil Vill VI
2 R 0 N~ Q-Q-A 1 15 HN 0 R R
12 R 0R4 O R1
Route 2
OH + F',CN h HO-Q-A'CN
IX OH 0 R2 O / 0 0 N CI N. COOMe B R R 15 R511N R Br R 12 R 14 R11 R5 R" '11~~ R
' R44 R1 R4 R12 1 R13 R13 13 R R2 R4 R1
|| III IV V
R2 R2 R2 0 0 0 N O-Q-A CNN -O-Q-A \_N U N O-Q-A CN N'OH 1 15 15 bH 15 R R R R H 2N R R HN 0 R' t R R' R 24 R' R'4 O5H, )2R R12 R 1412 1 R 13 R 13 R 13 VII VilI Example 1 LXF-32:
0 ,\NN 0 N NH
cI CI
1 (LXF-32)
Synthesis of intermediate VI-1:
CI 0~ C :CI C1I C1C1 N CI CN C 0
Il-1 Ill-1 IV-1
0 0 C\ 0 I Br No ONH N \i I I CI! CI CI VI-1 V-1 At 0 °C, aqueous potassium carbonate solution (3 N, 182 mmol) was added dropwise to a stirring solution of hydroxylamine hydrochloride (182 mmol) in ethanol (100 mL), 2,6 dichlorobenzaldehyde (20 g, 114 mmol) was dissolved in 100 ml of ethanol, and then added to the hydroxylamine solution. The temperature was raised to 90°C and the mixture was reacted for two hours. The mixture was cooled to room temperature and then concentrated to a solid. A water/ethanol (1000 mL/100 mL) solution was added and the solid was stirred to break up, filtered, and dried under vacuum at 50 °C overnight to obtain a compound intermediate (18.4 g). This intermediate was dissolved in N,N-dimethylformamide (50 mL), and added dropwise to N-chlorosuccinimide (97 mmol) solution in N,N-dimethylformamide (100 mL) at 0 °C and stirred overnight. The reaction solution was poured into ice water at0°C, and then extracted with methyl tert-butyl ether (200 mL each time, 3 times in total), the organic phase was washed with saturated brine, and concentrated to obtain a crude product. N-hexane (600 mL) was added to the flask containing the crude product, stirred with a magnetic stir bar, filter, and the solid was dried under vacuum (30 °C.) to obtain Intermediate III-1 (18.3 g, yield 73%). 1H NMR (400 MHz, CDCl3) 6 7.43 - 7.39 (m, 2H), 7.39 - 7.33 (m, 1H). Triethylamine (8.2 g) was added to methyl 3-cyclopropyl-3-oxopropionate (82 mmol) and stirred for 30 minutes. Then the mixture was cooled to 10 °C, and a solution of III-1 (18.3 g, 82 mmol) in absolute ethanol (80 mL) was added dropwise (internal temperature did not exceed 30°C), and the reaction was kept overnight at room temperature. The reaction solution was diluted by adding ethyl acetate (100 mL), washed with water, and the aqueous phase was extracted with ethyl acetate (100 mL each time, 3 times in total). The organic phases were mixed, washed with saturated brine, and concentrated. 100 mL of ether was added to the concentrate and stirred, and the solvent was removed under vacuum to obtain solid product IV-1 (21.6 g, yield 84%). 1 H NMR (400 MHz, CDCl3) 6 7.43 - 7.39 (m, 2H), 7.39 - 7.33 (m, 1H), 3.72 (s, 3H), 2.21 - 2.09 (m, 1H), 1.35 - 1.28 (m, 2H), 1.25 - 1.18 (m, 2H). IV-1 (21.6 g, 69 mmol) was dissolved in tetrahydrofuran (140 mL) and cooled to 0 °C. A solution of diisobutylaluminum hydride (1.5 M, 102mL) in toluene was slowly added and the reaction solution is stirred at room temperature for 6h. The reaction solution was slowly poured into ice water, and IM aqueous hydrochloric acid solution was added to adjust the pH to about 2. The mixture was extracted with ethyl acetate (100 mL each time, three times in total), concentrated, and subjected to column chromatography to obtain the intermediate alcohol. This intermediate and triphenyl phosphine (59 mmol) were dissolved in dichloromethane (60 mL) and cooled to 0 °C, and a solution of carbon tetrabromide (62 mmol) in dichloromethane (60 mL) was added dropwise under the protection of nitrogen and reacted at room temperature for 4 h. The solvent was removed from the reaction solution to obtain an oily substance, which was subjected to column chromatography to obtain intermediate V-1 (15.3 g, yield 96%). 1 H NMR (400 MHz, CDCl3) 6 7.49 - 7.44 (m, 2H), 7.43 - 7.37 (m, 1H), 4.25 (d, J= 1.3 Hz, 2H), 2.21 - 2.09 (m, 1H), 1.35 - 1.28 (m, 2H), 1.25 - 1.18 (m, 2H). At 0 °C, potassium tert-butoxide (6.5 mmol) was added to a solution of tert-butyl 4 hydroxypiperidine-1-carboxylate (1.3 g, 6.5 mmol) in anhydrous tetrahydrofuran (20 mL) and stirred for 30 minutes, and then a solution of V-1 (4.3 mmol) in anhydrous tetrahydrofuran (5 mL) was added dropwise, and the reaction was carried out for 8 h. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (15 mL each time, 3 times in total), the organic phase was washed with saturated brine, concentrated, and subjected to column chromatography to obtain intermediate tert-butyl 4-((5-cyclopropyl)-3-(2,6 dichlorophenyl)isoxazo-4-yl)methoxy)piperidine-1-carboxylate (1.55 g). Intermediate tert butyl 4-((5-cyclopropyl)-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)piperidine-1 carboxylate (1.55 g , 3.3 mmol) was dissolved in dichloromethane (8 mL)and cooled to 0°C, and trifluoroacetic acid (8 mL) was added dropwise and stirred at room temperature for 3h. The solvent was removed under vacuum, and the residue was dissolved in ethyl acetate (20 mL), washed with 2 N sodium hydroxide solution, saturated brine, and the solvent was removed to obtain intermediate VI-1 (1.0 g, yield 72%). 'H NMR (400 MHz, CDCl3) 6 7.47 7.43 (m, 2H), 7.42 - 7.36 (m, 1H), 4.23 (s, 2H), 3.55 - 3.49 (m, 1H), 3.02 - 2.91 (m, 4H), 2.10 - 2.02 (m, 1H), 1.93 - 1.76 (m, 2H), 1.75 - 1.62 (m, 2H), 1.26 - 1.06 (m, 4H). Synthesis of Example Compound 1, namely LXF-32:
0 N N NH Br CN O NNN
NC VI-1 CN
V-N \ O N N~ \ N
Viln1 H->N OHHN
Intermediate VI-1 (1.0 g, 2.7 mmol), 3-bromobenzonitrile (4.1 mmol), sodium tert butoxide (5.4 mmol), palladium acetate (0.14 mmol), and 1,1'-binaphthalene-2,2' bisdiphenylphosphine (0.27 mmol) were added to around bottom flask, and toluene (80mL) was added under the protection of nitrogen, heated to reflux, and reacted overnight. The reaction solution was cooled to room temperature, and added with water, extracted, concentrated, and subjected to column chromatography to obtain intermediate VII-1 (0.55 g, yield 43%). 1HNMR (400 MHz, CDCl3)7.40 (d, J=1.2Hz, 1H), 7.38 (s, 1H), 7.32 - 7.28 (in,2H), 7.09 - 7.02 (in,3H), 4.34 (s, 2H), 3.47- 3.41(n, 1H), 3.31 -3.20 (in,2H), 2.97 -2.87 (in,2H),2.18 -2.11(n, 1H), 1.83 -1.72 (in,2H), 1.26 (qt, J= 10.1, 5.1 Hz, 4H), 1.13 (ddd, J = 11.4,7.0,4.4Hz, 2H).
VII-1(0.4 g, 0.9 mmol), hydroxylamine hydrochloride (2.3mmol), and absolute ethanol (smL) were added into a round bottom flaskand stirred. Triethylamine (2.3 mmol) wasslowly added dropwise, andheatedto 80°C toreact for4h. Afterthe mixturewas cooledto room temperature, the solvent was removed, and the residue was dissolved in ethyl acetate (15 mL), and washedwith water andsaturated brine.Theorganic phase wasconcentrated,and subjected tosilicagel column chromatography to obtain intermediate3-(4-((5-cyclopropyl-3-(2,6 dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-N'-hydroxybenzamidine VIII-1 (0.41 g, yield 96 ). 3-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-N' hydroxybenzamidine VIII-1 (0.41 g, 0.83mmol), N,N'-carbonyldiimidazole (1.0 mmol), and 1,4-dioxane (4 mL) were added to a round bottom flask, and then 1,8 diazabicyclo[5.4.0]undec-7-ene (0.91 mmol) was added, heated to 100 °C and reacted for 3 hours. The reaction solution was cooled to room temperature, diluted with water (5 mL), adjusted to pH approximately equal to 2 with a IM aqueous hydrochloric acid solution, and then extracted with ethyl acetate (4 mL each time, 3 times in total). The organic phases were combined, washed with saturated brine, and concentrated and the crude product obtained was subjected to silica gel column chromatography to obtain the final product 1 (0.28 g, yield 64%). 1H NMR (400 MHz, CDC3) 67.37 (d, J= 7.5 Hz, 2H), 7.31 - 7.26 (m, 2H), 7.17 (d, J = 10.4 Hz, 2H), 7.07 (d, J= 7.5 Hz, 1H), 6.91 (d, J= 7.6 Hz, 1H), 4.33 (s, 2H), 3.38 (m, 1H),
3.21 (m, 2H), 2.83 (t, J= 8.6 Hz, 2H), 2.15 (m, 1H), 1.73 (m, 2H), 1.51 (m, 2H), 1.26 (m, 4H), 1.13 (m, 2H). MS(ESI, m/z): 541[M+H]+. Example 2:
0
ci c NN'O HN
0 2 Example 2 was carried out by referring to the operation of example 1. The compound was prepared from intermediate VI-1 via route 1. The synthetic route was as follows. Synthesis of Example Compound 2: ~CN O- NH Br"IN
CI CI ci cI CN
VI-1 V VII-2
0 0 N N....NN N. C/ CI'OH C1 C N0 N H 2N HN-0 VIII-2 2
Compound 2 was synthesized from raw material VI-1 according to the synthetic method of compound 1, wherein VIII-2, white solid, yield 42%; 1H NMR (400 MHz, CDC3) 6 7.49 (d, J= 8.7 Hz, 2H), 7.36 (d, J= 7.7 Hz, 2H), 7.30 - 7.25 (m, 1H), 6.81 (d, J= 8.7 Hz, 2H), 5.01 (s, 2H), 4.34 (s, 2H), 3.46 - 3.36 (m, 1H), 3.33 - 3.22 (m, 2H), 2.98 - 2.84 (m, 2H), 2.20 - 2.12 (m, 1H), 1.81 1.73 (m, 2H), 1.59 - 1.48 (m, 2H), 1.28 - 1.23 (m, 2H), 1.15 - 1.08 (m, 2H). MS (EI,m/z): 501[M-H]+. Compound 2, white solid, yield 7 1 %, 1H NMR (400 MHz, CDCl3) 6 7.64 (d, J= 9.0 Hz, 2H), 7.44 - 7.36 (m, 2H), 7.31 (dd, J= 8.9, 7.1 Hz, 1H), 6.90 (d, J= 9.1 Hz, 2H), 4.37 (s, 2H), 3.50 (tt, J= 7.2, 3.5 Hz, 1H), 3.43 - 3.32 (m, 2H), 3.13 - 2.99 (m, 2H), 2.16 (d, J= 30.8 Hz, 1H), 1.85 - 1.73 (m, 2H), 1.61 - 1.50 (m, 2H), 1.32 - 1.25 (m, 4H), 1.15 (m, 2H); MS(ESI,m/z):
527[M+H]+. Example 3:
P 0 N
cl s CI HN O \ 0 3 Example 3 was carried out by referring to the operation of example 1. The compound was prepared from intermediate V- Ivia route 1. The synthetic route was as follows. OH
0 '\ Br N 0 0 NCI C Boc N 0 NH B C N Br N N.. C1 CI Br cl CI CN
V-1 VI-3 / VII-3
0-0 0 N \ N. - N \/ C/ C N NOHCDI C IO N N NH2 HN O
VIl1-3 3 O At 0°C, potassium tert-butoxide (6.5 mmol) was added to a solution of tert-butyl 4 hydroxyhexahydroazepine--carboxylate (6.5 mmol) in anhydrous tetrahydrofuran (20 mL) and stirred for 30 minutes, and then a solution of V-1 (4.3 mmol) in anhydrous tetrahydrofuran (5 mL) was added dropwise, and the reaction was carried out for 8 h. Water (20 mL) was added to the reaction solution, which was then extracted with ethyl acetate (15 mL each time, 3 times in total). The organic phase was washed with saturated brine, concentrated, and subjected to column chromatography to obtain an intermediate. The intermediate was dissolved in dichloromethane (8 mL) and cooled to 0°C, and trifluoroacetic acid (8mL) was added dropwise, and stirred at room temperature for 3h. The solvent was removed under vacuum, ethyl acetate (20 mL) was added to dissolve, washed with 2N sodium hydroxide solution, saturated brine, and the solvent was removed to obtain intermediate VI-3 (0.87 g, yield 53%). 'H NMR (400 MHz, CDCl3) 6 7.45 - 7.40 (m, 2H), 7.38 - 7.32 (m, 1H), 4.35 - 4.23 (m, 2H), 3.49 - 3.42 (m, 1H), 3.40 - 3.18 (m, 4H), 2.18 - 2.09 (m, 1H), 1.83 - 1.59 (m, 5H), 1.55 - 1.46 (m, 1H), 1.28 - 1.23 (m, 2H), 1.16 - 1.10 (m, 2H). Intermediate VI-3 (0.8 g), 4-bromobenzonitrile (4.1 mmol), sodium tert-butoxide (5.4 mmol), palladium acetate (0.14 mmol), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (0.27 mmol) were added to a round bottom flask, and toluene (60 mL) was added under the protection of nitrogen, heated to reflux, and reacted overnight. The reaction solution was cooled to room temperature and water was added. The mixture was extracted, concentrated, and subjected to column chromatography to obtain intermediate VII-3 (0.49 g, yield 48%). 'H NMR (400 MHz, CDCl3) 6 7.44 - 7.40 (m, 2H), 7.37 - 7.33 (m, 1H), 7.27 - 7.21 (m, 1H), 6.92
- 6.86 (m, 1H), 6.83 - 6.78 (m, 2H), 4.34 - 4.24 (m, 2H), 3.49 - 3.43 (m, 1H), 3.39 - 3.18 (m, 4H), 2.18 - 2.10 (m, 1H), 1.84 - 1.58 (m, 5H), 1.55 - 1.48 (m, 1H), 1.27 - 1.24 (m, 2H), 1.15 1.09 (m, 2H). Compound 3 was synthesized from VII-3 as the raw material according to the synthesis method of compound 1, yield 66%, 'H NMR (400 MHz, CDCl3) 6 7.42 - 7.38 (m, 2H), 7.36 7.31 (m, 1H), 7.30 - 7.25 (m, 1H), 7.03 - 6.99 (m, 2H), 6.82 - 6.75 (m, 1H), 4.35 - 4.23 (m, 2H), 3.48 - 3.20 (m, 5H), 2.18 - 2.10 (m, 1H), 1.89 - 1.57 (m, 5H), 1.55 - 1.45 (m, 1H), 1.26 1.21 (m, 2H), 1.15 - 1.08 (m, 2H). MS(ESI,m/z): 541[M+H]+. Example 4:
0 N- 0 O CN N O H C1 CI
4 Example 4 was carried out by referring to the operation of example 1. The compound was prepared from intermediate VI-3 via route 1. The synthetic route was as follows.
NH CN-0N I. NN I_ o _ N\/ /NNO
Br CDI H CI CI CI CI CI CI
VI-3 4
Compound 4 was synthesized from VI-3 as the raw material according to the synthesis method of compound 1, wherein, VII-4, white solid, yield 59%, H NMR (400 MHz, CDCl3)6 7.45 - 7.40 (m, 4H), 7.37 - 7.32 (m, 1H), 6.60 (d, J= 9.1 Hz, 2H), 4.33 - 4.24 (m, 2H), 3.52 - 3.19 (m, 5H), 2.17 - 2.09 (m, 1H), 1.82 - 1.60 (m, 5H), 1.51 - 1.43 (m, 1H), 1.29 - 1.24 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 4, white solid, yield 69%, IH NMR (400 MHz, CDCl3)6 7.60 (d, J= 8.9 Hz, 2H), 7.44 - 7.39 (m, 2H), 7.38 - 7.33 (m, 1H), 6.66 (d, J= 9.1 Hz, 2H), 4.35 - 4.23 (m, 2H), 3.51 - 3.19 (m, 5H), 2.18 - 2.08 (m, 1H), 1.83 - 1.59 (m, 5H), 1.54 - 1.45 (m, 1H), 1.28 - 1.23 (m, 2H), 1.15 1.08 (m, 2H). MS(ESI,m/z): 541[M+H]+. Example 5:
0 5 Example 5 was carried out by referring to the operation of example 1. The compound was prepared from intermediate V- Ivia route 1. The synthetic route was as follows.
I0 ' Br \ Br H Boc O Br CN C CI CI CI NH _____
V-1 VI-5
CI ci CI CI HN O
VIl-5 5 Compound 5 was synthesized from V- Ias the raw material according to the synthesis method of compound 1, wherein VI-5, colloid, yield 61%, 'H NMR (400 MHz, CDCl3) 6 7.45 - 7.40 (m, 2H), 7.39 - 7.32 (m, 1H), 4.36 - 4.22 (m, 2H), 3.98 - 3.92 (m, 1H), 3.40 - 3.13 (m, 4H), 2.17 - 2.08 (m, 1H), 1.83 - 1.73 (m, 2H), 1.31 -1.24 (m, 2H), 1.17 - 1.11 (m, 2H). VII-5, white solid, yield 49%, H NMR (400 MHz, CDC3) 6 7.33 (dd, J= 7.5,1.8 Hz,1H), 7.27 - 7.19 (m, 3H), 6.94 (d, J= 7.5 Hz, 1H), 6.66 - 6.59 (m, 2H), 4.40 - 4.28 (m, 2H), 4.19 - 4.13 (m, 1H), 3.35 - 3.18 (m, 3H), 3.04 (d, J= 10.5 Hz, 1H), 2.18 - 2.09 (m, 1H), 2.04 - 1.97 (m, 2H), 1.30 - 1.25 (m, 2H), 1.16 - 1.11 (m, 2H). 5, white solid, yield 63%, 'H NMR (400 MHz, CDCl3) 6 7.33 - 7.13 (m, 4H), 7.06 (d, J = 7.8 Hz, 1H), 6.83 (s, 1H), 6.62 - 6.57 (m, 1H), 4.39 - 4.29 (m, 2H), 3.38 - 3.32 (m,1H), 3.31
-3.19 (m, 2H), 3.11 (d, J= 10.3 Hz, 1H),2.18 - 2.10 (m, 1H), 2.01 - 1.94 (m, 2H), 1.26 - 1.22 (m,2H), 1.16 - 1.09 (m, 2H).MS(ESI, m/z): 513[M+H]+. Example 6:
CI CI 0
6
Example 6 was carried out by referring to the operation of example 1. The compound was prepared from intermediate VI-5 via route 1. The synthetic route was as follows.
NON N-0
CN ClO H C0 )Br CN O CN HONH3CI N- O C N
CI CI CDI CI ci
S VII-6 6 Compound 6 was synthesized from VI-5 as the raw material according to the synthesis method of compound 1, wherein, VII-6, white solid, yield 38%. 'H NMR (400 MHz, CDCl3) 6 7.46 (d, J= 8.9 Hz, 2H), 7.31 (dd, J= 7.9, 1.2 Hz, 1H), 7.25 (dd, J= 8.1, 1.2 Hz, 1H), 7.18 (t, J= 7.9 Hz, 1H), 6.40 (d,
J= 8.9 Hz, 2H), 4.40 - 4.28 (m, 2H), 4.19 - 4.12 (m, 1H), 3.37 - 3.22 (m, 3H), 3.11 (d, J= 11.0 Hz, 1H), 2.17 - 1.93 (m, 3H), 1.31 - 1.26 (m, 2H), 1.18 - 1.11 (m, 2H). 6, white solid, yield 69%. H NMR (400 MHz, DMSO-d6) 6 7.59 (d, J= 8.8 Hz, 2H), 7.54 - 7.39 (m, 3H), 6.53 (d, J= 8.8 Hz, 2H), 4.32 (q, J= 12.1 Hz, 2H), 4.10 (s, 1H), 3.31 3.23 (m, 2H), 3.12 - 3.04 (m, 2H), 2.39 - 2.28 (m, 1H), 2.02 - 1.84 (m, 2H), 1.15 - 1.06 (m, 4H). MS(ESI,m/z): 513[M+H]+. Example 7:
0
CI CIO N N' NH CF ci HN- \
7
Example 7 was carried out by referring to the operation of example 1. The compound was prepared from intermediate V- Ivia route 1. The synthetic route was as follows.
0 HO-/-;;\ NCN Br HO N'Boc NH Br ci c I ~ ci ci
V-1 VI-7
C CIO N ON HO-NH3CI C C c C HN# O
VII-7 7
Compound 7 was synthesized from V- Ias the raw material according to the synthesis method of compound 1, wherein, VI-7, colloid, yield 67%. 'H NMR (400 MHz, CDCl3) 6 7.42 - 7.39 (m, 2H), 7.36 - 7.31 (m, 1H), 4.27 - 4.18 (m, 2H), 4.10 - 3.96 (m, 2H), 3.53 (t, J= 4.7 Hz, 1H), 2.16 - 2.07 (m, 1H), 1.91 - 1.69 (m, 6H), 1.64 (d, J= 14.4 Hz, 2H), 1.26 - 1.22 (m, 2H), 1.14 - 1.08 (m, 2H). VII-7, white solid, yield 54%. IH NMR (400 MHz, CDCl3) 6 7.47 - 7.42 (m, 4H), 7.38 - 7.34 (m, 1H), 6.65 (d, J= 8.9 Hz, 2H), 4.26 (s, 2H), 4.13 - 4.10 (m, 2H), 3.46 - 3.41 (m, 1H), 2.17 2.09 (m, 1H), 1.97 - 1.81 (m, 6H), 1.66 - 1.61 (m, 2H), 1.28 - 1.25 (m, 2H), 1.17 - 1.11 (m, 2H). 7, white solid, yield 77%. 'H NMR (400 MHz, CDCl3) 6 7.60 (d, J= 8.8 Hz, 2H), 7.44 7.40 (m, 2H), 7.37 - 7.32 (m, 1H), 6.70 (d, J= 9.0 Hz, 2H), 4.25 (s, 2H), 4.12 - 4.08 (m, 2H), 3.42 (s, 1H), 2.18 - 2.10 (m, 1H), 1.99 - 1.82 (m, 6H), 1.61 (d, J= 14.4 Hz, 2H), 1.26 - 1.22 (m, 2H), 1.16 - 1.10 (m, 2H). MS(ESI,m/z): 553[M+H]+. Example 8:
HN - 0 8 (LXF-116)
Example 8, i.e., the preparation of LXF-116 was carried out by referring to the operation of example 1. The compound was prepared from intermediate 11-8 via route 1. The synthetic route was as follows.
OH PH 0 0N Br Boc CF 3 3 '0CF 0& F 3C F3C
11-8 111-8 IV-8 V-8
P 0 0 NH \ ON NN, F 3C F 3C CN CF3 HN4 - 0 VI-8 Vii-8 8
Compound 8 was synthesized from 11-8 as the raw material according to the synthesis method of compound 1, wherein, IV-8, white solid, yield 58%. H NMR (400 MHz, CDCl3)6 7.82 (d, J= 7.5 Hz, 1H), 7.74 - 7.59 (m, 2H), 7.56 (d, J= 7.5 Hz, 1H), 3.3.73 (s, 3H), 2.19 - 2.09 (m, 1H), 1.33 - 1.27 (m, 2H), 1.24 - 1.15 (m, 2H). V-8, colourless liquid, yield 88%. 1H NMR (400 MHz, CDCl3)6 7.84 (d, J= 7.4 Hz, 1H), 7.73 - 7.61 (m, 2H), 7.57 (d, J= 7.4 Hz, 1H), 4.23 (s, 2H), 2.17 - 2.09 (m, 1H), 1.32 - 1.27 (m, 2H), 1.23 - 1.17 (m, 2H). VI-8, colloid, yield 78%.1 H NMR (400 MHz, CDCl3) 6 7.79 (d, J= 7.0 Hz, 1H), 7.66 7.56 (m, 2H), 7.41 (d, J= 7.0 Hz, 1H), 4.23 (s, 2H), 3.55 - 3.49 (m, 1H), 3.03 - 2.91 (m, 4H), 2.10 - 2.02 (m, 1H), 1.94 - 1.77 (m, 2H), 1.75 - 1.64 (m, 2H), 1.25 - 1.07 (m, 4H). VII-8, white solid, yield 48%.1 H NMR (400 MHz, CDCl3) 6 7.77 (d, J= 7.2 Hz, 1H), 7.62 - 7.51 (m, 2H), 7.48 - 7.40 (m, 3H), 6.79 (d, J= 9.0 Hz, 2H), 4.27 (s, 2H), 3.49 - 3.35 (m, 3H), 3.12 - 2.96 (m, 2H), 2.16 - 2.07 (m, 1H), 1.85 - 1.70 (m, 2H), 1.58 - 1.46 (m, 2H), 1.23 1.18 (m, 2H), 1.13 - 1.06 (m, 2H). 8, white solid, yield 72%. 1H NMR (400 MHz, DMSO-d6) 6 7.88 (d, J= 7.6 Hz, 1H), 7.80 - 7.67 (m, 2H), 7.64 - 7.56 (m, 3H), 6.99 (d, J= 8.8 Hz, 2H), 4.28 (s, 2H), 3.46 - 3.37 (m, 3H), 3.04 - 2.94 (m, 2H), 2.35 - 2.25 (m, 1H), 1.70 (s, 2H), 1.41 - 1.27 (m, 2H), 1.17 - 1.03 (m, 4H). MS(ESI,m/z): 527[M+H]+. Example 9:
OCF 3 I HN 0 9
Example 9 was carried out by referring to the operation of example 1. The compound was prepared from intermediate 11-9 via route 1. The synthetic route was as follows. OH
N CI O\ \ Br OCF3 OCF3 O
I& F 3CO F 3CO N 0 Boc
11-9 111-9 V-9 V-9
O NH NN F 3CO O F 3CO O N CN OCF, N N-O
VI-9 V9 I VII-9 9
Compound 9 was synthesized from 11-9 as the raw material according to the synthesis method of compound 1, wherein, IV-9, white solid, yield 59%. H NMR (400 MHz, CDCl3) 6 7.66 - 7.50 (m, 2H), 7.49 7.41 (m, 2H), 3.70 (s, 2H), 2.18 - 2.10 (m, 1H), 1.31 - 1.26 (m, 2H), 1.23 - 1.17 (m, 2H). V-9, colourless liquid, yield 82%. 'H NMR (400 MHz, CDCl3)6 7.65 - 7.52 (m, 2H), 7.49 - 7.40 (m, 2H), 4.36 (s, 2H), 2.18 - 2.10 (m, 1H), 1.31 - 1.26 (m, 2H), 1.23 - 1.17 (m, 2H). VI-9, colloid, yield 80%. 'H NMR (400 MHz, CDC3) 67.45 - 7.30 (m, 4H), 4.29 - 4.18 (m, 2H), 2H), 3.50 - 3.36 (m, 3H), 3.12 - 3.00 (m, 2H), 2.18 - 2.10 (m, 1H), 1.86 - 1.76 (m, 2H), 1.61 - 1.50 (m, 2H), 1.28 - 1.22 (m, 2H), 1.13 - 1.07 (m, 2H). VII-9, white solid, yield 55%. 'H NMR (400 MHz, CDCl3) 6 7.58 - 7.47 (m, 2H), 7.45 7.34 (m, 4H), 6.81 (d, J= 9.0 Hz, 2H), 4.28 (s, 2H), 3.50 - 3.38 (m, 3H), 3.14 - 3.00 (m, 2H), 2.18 - 2.10 (m, 1H), 1.85 - 1.76 (m, 2H), 1.61 - 1.50 (m, 2H), 1.27 - 1.22 (m, 2H), 1.13 - 1.07 (m, 2H). 9, white solid, yield 69%. H NMR (400 MHz, DMSO) 6 7.69 - 7.48 (m, 6H), 7.00 (d, J = 8.9 Hz, 2H), 4.37 (s, 2H), 3.55 - 3.40 (m, 3H), 3.06 - 2.96 (m, 2H), 2.37 - 2.28 (m, 1H), 1.80
- 1.69 (m, 2H), 1.44 - 1.31 (m, 2H), 1.16 - 1.03 (m, 4H). MS(EsI,m/z): 543[M+H]+.
Example 10:
| HN40
10
The synthetic route of example 10 was as follows.
OH N~0 0 IC 0 '\ Br CI O N IX-10 CI CI CI CI CI
lil-1 IV-10 V-10
0\ 0
C/ N CO N CN CI C/N-O HN0
VIl-10 10
HO NH+ HO N CN
F IX-1O At 0 °C, sodium methoxide/methanol solution (5.4 M, 4.1 mL) was slowly added dropwise into a solution of methyl acetoacetate (22.2 mmol) in anhydrous tetrahydrofuran (10ml), and then a solution of III-1 (5 g, 22.2 mmol) ) in anhydrous tetrahydrofuran (10 mL) was added and stirred at room temperature for 12 h. Ethyl acetate (40 mL) was added to the reaction solution, the organic phase was washed with water and saturated brine, and the solvent was removed to obtain an oily substance, which was then subjected to column chromatography to obtain intermediate IV-10 (3.4 g, yield 54%). IH NMR (400 MHz, CDC3) 6 7.45 - 7.41 (m, 2H), 7.39 - 7.34 (m, 1H), 3.71 (s, 3H), 2.82 (s, 3H). 4-fluorobenzonitrile (2 g, 16.5 mmol), 4-hydroxypiperidine (18.2 mmol), anhydrous potassium carbonate (41.3 mmol) and DMSO (16 mL) were added to a round bottom flask, heated to 130°C, and reacted for 12h. The mixture was cooled to room temperature, added with 30 mL of water, and filtered. The solid was washed with water to obtain intermediate IX-10 (3.1 g, yield 93%). 1H NMR (400 MHz, CDC3) 67.52 - 7.43 (m, 2H), 6.91 - 6.80 (m, 2H), 4.00 - 3.91 (m, 1H), 3.77 - 3.63 (m, 2H), 3.13 (ddd, J= 13.0, 9.4, 3.3 Hz, 2H), 2.05 - 1.95 (m, 2H), 1.70 - 1.59 (m, 2H). The compound intermediate V-10 was synthesized by IV-10 as the raw material according to the synthesis method of the compound V-1. At0°C, potassium tert-butoxide (6.5 mmol) was added to a solution of IX-10 (1.3 g, 6.5 mmol) in anhydrous tetrahydrofuran (20 ml) and stirred for 30 minutes, and then a solution of V-10 (4.3 mmol) in anhydrous tetrahydrofuran (5mL) was added dropwise and reacted for 8h. Water (20 mL) was added to the reaction solution, which was then extracted with ethyl acetate (15 mL x 3). The organic phase was washed with saturated brine, concentrated, and subjected to column chromatography to obtain intermediate VII-10 (1.21 g, yield 64%). 1H NMR (400 MHz, CDC3) 67.47 (d, J= 9.0 Hz, 2H), 7.42 - 7.38 (m, 2H), 7.33 7.29 (m, 1H), 6.80 (d, J= 9.0 Hz, 2H), 4.28 (s, 2H), 3.51 - 3.43 (m, 1H), 3.37 - 3.29 (m, 2H), 3.12 - 2.97 (m, 2H), 2.55 (s, 3H), 1.78 - 1.72 (m, 2H), 1.59 - 1.49 (m, 2H). Compound 10 was synthesized from VII-10 as the raw material according to the synthesis method of compound 1, white solid, yield 64%.1 H NMR (400 MHz, CDCl3) 6 7.64 (d, J= 8.9 Hz, 2H), 7.45 - 7.36 (m, 2H), 7.34 - 7.28 (m, 1H), 6.88 (d, J= 8.9 Hz, 2H), 4.29 (s, 2H), 3.51
- 3.27 (m, 3H), 3.14 - 2.99 (m, 2H), 2.55 (s, 3H), 1.85- 1.70(m, 2H), 1.62- 1.47(m, 2H). MS(ESI,m/z): 501[M+H]+ Example 11:
0
CI N CIO0 /N N'O HN-4 0 11
The synthetic route of example 11 was as follows.
OH 0\ 00 B NCI Br HO-QN-QCN CI CI O CI CI cI CI
Ill-1 IV-11 V1I
0 0\ N.. NN N CN N, CI N Cl N 0 CN -CI N CIO N0 HN0
VIl-11 11
Compound intermediate IV-1( yield 61%) was synthesized from 111-1 as the raw material according to the synthesis method of compound IV-10, wherein, methyl acetoacetate was replaced by methyl isobutyryl acetate. 1H NMR (400 MHz, CDCl3) 6 7.44 - 7.41 (m, 2H), 7.38 - 7.33 (m, 1H), 3.95 - 3.83 (m, 1H), 3.69 (s, 3H), 1.46 (d, J= 7.0 Hz, 6H). Compound intermediate VII-11 was synthesized from IV-11 as the raw material according to the synthesis method of compound VII-10, white solid, yield 71 %; 1 H NMR (400 MHz, CDC3) 6 7.43 - 7.38 (m, 2H), 7.37 - 7.32 (m, 2H), 7.28 - 7.23 (m, 1H), 6.79 - 6.71 (m, 2H), 4.23 (s, 2H), 3.46 - 3.36 (m, 1H), 3.34 - 3.23 (m, 2H), 3.07 - 2.98 (m, 2H), 1.73 - 1.63 (m, 2H), 1.50 - 1.45 (m, 2H), 1.38 (d, J= 7.1 Hz, 6H). Compound 11 was synthesized from VII-1 1as the raw material according to the synthesis method of compound 1, white solid, yield 66%. 1H NMR (400 MHz, CDC3) 6 7.63 (d, J= 8.9 Hz, 2H), 7.43 - 7.37 (m, 2H), 7.34 - 7.27 (m, 1H), 6.87 (d, J= 9.0 Hz, 2H), 4.29 (s, 2H), 3.50 - 3.29 (m, 4H), 3.12 - 2.98 (m, 2H), 1.80 - 1.69 (m, 2H), 1.59 - 1.47 (m, 2H), 1.43 (d, J= 7.0 Hz, 6H). MS(ESI,m/z): 529[M+H]+. Example 12:
0N / \
CI CIN HN4 0 12
The synthetic route of example 12 was as follows.
OH N CI 0 O 0 O \ Br HOJNJCN N 0OC- C CI CI 0 CI N CI CI CI
ll-1 IV-12 V-12
0\
/ N Nj\
CI N C/O N CN CN N / HN-0O
VII-12 12
Compound intermediate IV-12 ( yield 67%) was synthesized from III- Ias the raw material according to the synthesis method of compound IV-10, wherein, methyl acetoacetate was replaced by methyl benzoylacetate. H NMR (400 MHz, CDC3) 68.10 (d, J= 7.9 Hz, 1H), 7.97 (d, J= 7.9 Hz, 1H), 7.58 - 7.44 (m, 5H), 7.41 - 7.36 (m, 1H), 3.65 (s, 3H). Compound intermediate VII-12 was synthesized from IV-12 as the raw material according to the synthesis method of compound VII-10, white solid, yield 74%; 'H NMR (400 MHz, CDC3) 67.95 (dd, J= 7.8, 1.7 Hz, 2H), 7.64 (d, J= 8.9 Hz, 2H), 7.59 - 7.51 (m, 3H), 7.49 - 7.44 (m, 2H), 7.42 - 7.35 (m, 1H), 6.90 (d, J= 8.9 Hz, 2H), 4.46 (s, 2H), 3.57 - 3.50 (m, 1H), 3.46 - 3.37 (m, 2H), 3.12 - 2.99 (m, 2H), 1.81 - 1.70 (m, 2H), 1.62 - 1.49 (m, 2H). Compound 12 was synthesized from VII-12 as the raw material according to the synthesis method of compound 1, white solid, yield 56%. IH NMR (400 MHz, CDC3) 6 11.50 (s, 1H), 7.95 (dd, J= 7.8, 1.7 Hz, 2H), 7.64 (d, J= 8.9 Hz, 2H), 7.59 - 7.51 (m, 3H), 7.49 - 7.44 (m, 2H), 7.42 7.35 (m, 1H), 6.90 (d, J= 8.9 Hz, 2H), 4.46 (s, 2H), 3.57 - 3.50 (m, 1H), 3.46 - 3.37 (m, 2H), 3.12 - 2.99 (m, 2H), 1.81 - 1.70 (m, 2H), 1.62 - 1.49 (m, 2H). MS(ESI, m/z): 562[M+H]+. Example 13:
0 '\ Na D/_ ,
CI CI N' If - HN4O 0 13
The synthetic route of example 13 was as follows.
+ IX-13
0 0 Br 0'
CI CI I 1 C1N CO -CN( D CNCN C1 CIO N0' \/ ,NN0 HN 4 O
V-1 VII-13 13
Compound intermediate IX-13 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 94%; 'H NMR (400 MHz, CDC 3) 68.37 (d, J= 2.0 Hz, 1H), 7.57 (dd, J= 9.1, 2.0 Hz, 1H), 6.62 (d, J = 9.1 Hz, 1H), 4.16 - 3.93 (m, 3H), 3.41 - 3.30 (m, 2H), 2.00 - 1.91 (m, 2H), 1.63 - 1.52 (m,
2H). Compound intermediate VII-13 was synthesized from V- Ias the raw material according to the synthesis method of compound VII-1, white solid, yield 74%; 'H NMR (400 MHz, CDC 3) 6 8.26 (d, J= 2.1 Hz, 1H), 7.47 (dd, J= 9.1, 2.1 Hz, 1H), 7.35 - 7.30 (m, 2H), 7.27 7.22 (m, 1H), 6.50 (d, J= 9.1 Hz, 1H), 4.27 (s, 2H), 3.66 - 3.56 (m, 2H), 3.45 - 3.40 (m, 1H), 3.36 - 3.24 (m, 2H), 2.13 - 2.04 (m, 1H), 1.65 - 1.58 (m, 3H), 1.45 - 1.35 (m, 2H), 1.16 - 1.12 (m, 2H), 1.07 - 1.00 (m, 2H). Compound 13 was synthesized from VII-13 as the raw material according to the synthesis method of compound 1, white solid, yield 71 %; 1 H NMR (400 MHz, CDC3) 6 8.52 (d, J= 2.4 Hz, 1H), 7.79 (dd, J= 9.1, 2.5 Hz, 1H), 7.45 - 7.31 (m, 3H), 6.67 (d, J= 9.1Hz, 1H), 4.38 (s, 2H), 3.81 - 3.67 (m, 2H), 3.61 - 3.50 (m, 1H), 3.46 - 3.33 (m, 2H), 2.17 (s, 1H), 1.82 - 1.68 (m, 2H), 1.59 - 1.45 (m, 2H), 1.31 - 1.27 (m, 2H), 1.19- 1.12 (m, 2H). MS(ESI,m/z): 528[M+H]+. Example 14:
0 -N -- )N, CI CI HN4 - 0
14
The synthetic route of example 14 was as follows. N CN
N CN HFHONH +
FU HO IX-14
Br0 0
CI c11 CI X-14 ci N \CN C1 \/INN -N C C N - O
V-1 VII-14 14
Compound intermediate IX-14 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 91%;1 H NMR (400 MHz, CDC 3) 6 8.26 (d, J= 3.0 Hz, 1H), 7.47 (d, J= 8.8 Hz, 1H), 7.09 (dd, J= 8.8, 3.0 Hz, 1H), 4.03 - 3.95 (m, 1H), 3.76 - 3.65 (m, 2H), 3.25 - 3.14 (m, 2H), 2.04 - 1.94 (m, 2H), 1.73 - 1.60 (m, 2H). Compound intermediate VII-14 was synthesized from V- Ias the raw material according to the synthesis method of compound VII-1, white solid, yield 71%; 'H NMR (400 MHz, CDC 3) 68.27 (d, J= 2.7 Hz, 1H), 7.50 (d, J= 8.9 Hz, 1H), 7.44 - 7.38 (m, 2H), 7.37 - 7.29 (m, 1H), 7.23 - 7.17 (m, 1H), 4.27 (s, 2H), 3.58 - 3.35 (m, 3H), 3.24 - 3.14 (m, 2H), 2.08 1.96 (m, 1H), 1.84 - 1.77 (m, 2H), 1.67 - 1.59 (m, 2H), 1.30 - 1.25 (m, 2H), 1.18 - 1.11 (m, 2H). Compound 14 was synthesized from VII-14 as the raw material according to the synthesis method of compound 1, white solid, yield 55%; 1 H NMR (400 MHz, CDC3) 6 8.29 (d, J= 2.7 Hz, 1H), 7.89 (d, J= 8.9 Hz, 1H), 7.44 - 7.39 (m, 2H), 7.33 (d, J= 7.1 Hz, 1H), 7.23 - 7.17 (m, 1H), 4.37 (s, 2H), 3.58 - 3.48 (m, 1H), 3.42 - 3.35 (m, 2H), 3.20 - 3.13 (m, 2H), 2.20 2.12 (m, 1H), 1.84 - 1.77 (m, 2H), 1.64 - 1.57 (m, 2H), 1.30 - 1.27 (m, 2H), 1.18- 1.12 (m, 2H). MS(ESI,m/z): 528[M+H]+. Example 15:
0
cl cI 0 N N'O0 HN
15
The synthetic route of example 15 was as follows.
HO NH F N NCN F HO IX-15
0 0 '\ Br P ,\ CI CIr C1 C O N- CN CI1 CIO N, N' NHN0
V-1 VII-15 15
Compound intermediate IX-15 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 78%; IH NMR (400 MHz, CDCl3) 6 7.41 - 7.34 (m, 2H), 6.96 (d, J= 8.9 Hz, 1H), 3.90 - 3.80 (m, 1H), 3.18 - 3.10 (m, 2H), 2.78 - 2.70 (m, 2H), 2.26 (s, 3H), 2.03 - 1.97 (m, 2H), 1.77 - 1.67 (m, 2H). Compound intermediate VII-15 was synthesized from V- Ias the raw material according to the synthesis method of compound VII-1, white solid, yield 62%; 1 H NMR (400 MHz, CDCl3) 6 7.38 - 7.33 (m, 4H), 7.30 - 7.25 (m, 1H), 6.87 (d, J= 8.2 Hz, 1H), 4.32 (s, 2H),3.43 - 3.34 (m, 1H), 2.94 - 2.85 (m, 2H), 2.65 - 2.56 (m, 2H), 2.20 (s, 3H), 2.16 - 2.09 (m, 1H),
1.82 - 1.74 (m, 2H), 1.61 - 1.52 (m, 2H), 1.22 - 1.18 (m, 2H), 1.11 - 1.05 (m, 2H). Compound 15 was synthesized from VII-15 as the raw material according to the synthesis method of compound 1, white solid, yield 65%; 1 H NMR (400 MHz, CDC3) 6 7.62 (d, J= 1.7 Hz, 1H), 7.59 - 7.54 (m, 1H), 7.46 - 7.42 (m, 2H), 7.38 - 7.32 (m, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.38 (s, 2H), 3.48 - 3.39 (m, 1H), 3.03 - 2.94 (m, 2H), 2.72 - 2.64 (m, 2H), 2.31 (s, 3H), 2.22 - 2.15 (m, 1H), 1.89 - 1.80 (m, 2H), 1.69 - 1.58 (m, 2H), 1.31 - 1.28 (m, 2H), 1.18 - 1.13 (m, 2H).MS(ESI,m/z): 541[M+H]+. Example 16:
N CI C/NN HN4 0 16
The synthetic route of example 16 was as follows. F F CN NH C N &C F HO" IX-16
Br 0 _ F 0\ o- F IX-16 N ~ N CI CI N / CN C CI N N HN-0
V-1 VII-16 16
Compound intermediate IX-16 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 78%;1 H NMR (400 MHz, CDCl3) 6 7.38 - 7.30 (m, 1H), 6.67 - 6.49 (m, 2H), 4.02 - 3.91 (m, 1H), 3.78 - 3.57 (m, 2H), 3.26 - 3.04 (m, 2H), 2.01 - 1.88 (m, 2H), 1.68 - 1.55 (m, 2H). Compound intermediate VII-16 was synthesized from V- Ias the raw material according to the synthesis method of compound VII-1, white solid, yield 67%; 'H NMR (400 MHz, CDC3) 6 7.41 - 7.37 (m, 2H), 7.37 - 7.28 (m, 2H), 6.59 - 6.45 (m, 2H), 4.34 (s, 2H), 3.55 3.47 (m, 1H), 3.37 - 3.28 (m, 2H), 3.16 - 3.05 (m, 2H), 2.19 - 2.10 (m, 1H), 1.78 - 1.70 (m, 2H), 1.59 - 1.48 (m, 2H), 1.28 - 1.22 (m, 2H), 1.16 - 1.10 (m, 2H). Compound 16 was synthesized from VII-16 as the raw material according to the synthesis method of compound 1, white solid, yield 61%; IH NMR (400 MHz, CDCl3) 6 10.12 (s, 1H), 7.71 (t, J= 8.8 Hz, 1H), 7.44 - 7.38 (m, 2H), 7.35 - 7.30 (m, 1H), 6.68 (dd, J= 9.1, 2.2 Hz, 1H), 6.53 (dd, J= 15.5, 2.2 Hz, 1H), 4.36 (s, 2H), 3.56 - 3.47 (m, 1H), 3.39 - 3.31 (m, 2H), 3.16 - 3.07 (m, 2H), 2.21 - 2.11 (m, 1H), 1.81 - 1.74 (m, 2H), 1.62 - 1.51 (m, 2H), 1.32 - 1.27 (m, 2H), 1.18 - 1.11 (m, 2H). MS(ESI,m/z): 545[M+H]+. Example 17:
\ o F NH The synthetic route of example 17 was as follows.
CN O N C HOONH F 7IX-17
, I~
" +
CI CIr CXC1O N N C CO N O,
F F V-1 Vl-17 17 Compound intermediate IX-17 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 55%; T H NMR (400 MHz, CDCl3) 6 6.43 - 6.32 (m, 2H), 4.08 - 3.98 (m, 1H), 3.71 - 3.62 (m, 2H), 3.27 - 3.17 (m, 2H), 2.02 - 1.94 (m, 2H), 1.70 - 1.61 (m, 2H). Compound intermediate VII-17 was synthesized from V-1I as the raw material according to the synthesis method of compound VII-1, white solid, yield 67%; 'H NMR (400 MHz, CDCl3) 6 7.43 - 7.39 (m, 2H), 7.36 - 7.30 (m, 1H), 6.34 - 6.27 (m, 2H), 4.35 (s, 2H), 3.60 0i -C N 3.50 (m, 1H), 3.35 - 3.26 (m, 2H), 3.19 \/C N, - 3.08 (m, 2H), 2.18 - 2.10 (m, \ 1H), 1.74 - 1.68 (m, 2H), 1.59 - 1.50 (m, 2H), 1.28 - 1.25 (m, 2H), 1.17 - 1.11 (m, 2H). Compound 17 was synthesized from VII- 16 as the raw material according to the synthesis method of compound 1, white solid, yield 73%; ' H NMR (400 MHz, CDCl3) 6 7.45 - 7.39 (m, 2H), 7.37 - 7.31 (m, 1H), 6.40 (d, J= 13.5 Hz, 2H), 4.36 (s, 2H), 3.58 - 3.48 (m, H), 3.36 3.27 (m, 2H), 3.18 - 3.07 (m, 2H), 2.22 - 2.10 (m, 1H), 1.79 - 1.70 (m, 2H), 1.61 - 1.52 (m, 2H), 1.30 - 1.26 (m, 2H), 1.18 - 1.12 (m, 2H). MS(ESI,m/z): 563[M+H]+. Example 18: NMR400~zCD~3)6.4- 632(nH)3.- 3.8iH).7-.6(n2).7
CI CI N0 1 H HN 18
The synthetic route of example 18 was as follows.
F CN N F)a CN HO NH F HO IX-18
0 0 Br 1A N IX-N N CI N CI N CI CN C C N N'O FF HN
V-1 Vl-18 18
Compound intermediate IX-18 was synthesized from 4-hydroxypiperidine as the raw material according to the synthesis method of compound IX-10, white solid, yield 61%; 1 H NMR(400MHz, DMSO) 6 7.62 - 7.47 (m, 2H), 7.08 (t,J=8.8 Hz, 1H), 3.71- 3.62 (m, 1H), 3.43 - 3.37 (m, 2H), 3.01 - 2.79 (m, 2H), 1.92 - 1.74 (m, 2H), 1.57 - 1.42 (m, 2H). Compound intermediate VII-18 was synthesized from V- Ias the raw material according to the synthesis method of compound VII-1, white solid, yield 63%; 1 H NMR (400 MHz, CDC 3) 6 7.43 - 7.38 (m, 2H), 7.35 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 6.86 (t, J= 8.6 Hz, 1H), 4.35 (s, 2H), 3.49 - 3.41 (m, 1H), 3.26 - 3.15 (m, 2H), 2.96 - 2.86 (m, 2H), 2.20 - 2.12 (m,1H), 1.86 - 1.77 (m, 2H), 1.65 - 1.55 (m, 2H), 1.30 - 1.26 (m, 2H), 1.16 - 1.09 (m, 2H). Compound 18 was synthesized from VII-16 as the raw material according to the synthesis method of compound 1, white solid, yield 65%; 1 H NMR (400 MHz, CDCl3) 6 7.50 - 7.39 (m, 4H), 7.36 - 7.30 (m, 1H), 6.94 (t, J= 8.5 Hz, 1H), 4.37 (s, 2H), 3.55 - 3.42 (m, 1H), 3.33 3.17 (m, 2H), 3.00 - 2.84 (m, 2H), 2.22 - 2.13 (m, 1H), 1.89 - 1.80 (m, 2H), 1.69 - 1.58 (m, 2H), 1.32 - 1.26 (m, 2H), 1.19 - 1.12 (m, 2H). MS(ESI,m/z): 545 [M+H]+. Example 19:
N' 0O N NH
19 The synthetic route of example 19 was as follows.
0
NON NH 0 ~I CN C N CIO NH CI N CI /N CI O- N N
VI.I VIl-1 19 Compound intermediate VII-19 was synthesized from VI-1 as the raw material according to the synthesis method of compound VII-1, white solid, yield 37%; 1 H NMR (400 MHz, CDC3) 6 7.67 (s, 1H), 7.56 (s, 1H), 7.37 (d, J= 7.9 Hz, 2H), 7.29 - 7.23 (m, 1H), 7.09 (d, J= 8.9 Hz, 1H), 6.93 (d, J= 8.9 Hz, 1H), 4.31 (s, 2H), 3.52 (s, 3H), 3.37 - 3.27 (m, 1H), 3.24 3.14 (m, 2H), 2.83 - 2.71 (m, 2H), 2.20 - 2.09 (m, 1H), 1.86 - 1.75 (m, 2H), 1.63 - 1.52 (m, 2H), 1.26 - 1.18 (m, 2H), 1.12 - 1.07 (m, 2H).
Compound 19 was synthesized from VII-19 as the raw material according to the synthesis method of compound 1, white solid, yield 29%;'HNMR(400 MHz, DMSO-d6)67.81 (s, 1H), 7.63 (d, J= 7.7 Hz, 2H), 7.55 - 7.50 (m, 1H), 7.43 (d, J= 9.0 Hz, 1H), 7.28 (s, 1H), 7.04 (d, J= 9.0 Hz, 1H), 4.33 (s, 2H), 3.83 (s, 3H), 3.35 (s, 1H), 3.09 (s, 2H), 2.80 - 2.72 (m, 2H), 2.04 - 1.95 (m, 1H), 1.75 (s, 2H), 1.50 - 1.41 (m, 2H), 1.20 - 1.07 (m, 4H). MS(ESI,m/z): 580 [M+H]+. Example 20:
CI C N I - HN 4S
20
The synthetic route of example 20 was as follows.
0\ 0 N N
cl N CIO N N'OH ' CI N CIO '0 11H2N HN4
VIII-2 20
VIII-2 (0.41 g, 0.83 mmol), N,N'-thiocarbonyldiimidazole (1.0 mmol) and 1,4-dioxane (4 mL) were added into a round bottom flask, and then 1,8-diazabicyclic[5.4.0]undecarbon-7-ene (0.91 mmol) was heated to 100 °C and reacted for 3 hours. The reaction solution was cooled to room temperature, diluted with water (5 mL), adjusted to pH approximately equal to 2 with a IM aqueous hydrochloric acid solution, and then extracted with ethyl acetate (4 mL each time, 3 times in total). The organic phases were combined, washed with saturated brine, concentrated and the crude product obtained was subjected to silica gel column chromatography to obtain the final product 20 (0.22 g, yield 49%). 'H NMR (400 MHz, CDCl3)6 7.44 - 7.37 (m, 3H), 7.34 - 7.30 (m, 1H), 6.89 (d, J= 8.9 Hz, 2H), 4.36 (s, 2H), 3.44 - 3.37 (m, 1H), 3.24 - 3.14 (m, 2H), 2.83 - 2.73 (m, 2H), 2.21 - 2.14 (m, 1H), 1.81 - 1.76 (m, 2H), 1.61 - 1.54 (m, 2H), 1.32 - 1.26 (m, 2H), 1.17 1.09 (m, 2H). MS(ESI,m/z): 543 [M+H]+.
Example 21:
CF N 1, HN40
21
The synthetic route of example 21 was as follows.
CFBr IX-13 C NC N N NO SCF, CF 3 N C-F 3
V-8 VII-21 21 0
Compound intermediate VII-21 was synthesized from V-8 and IX-13 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 62%; 1H NMR (400 MHz, CDC3) 68.37 (d, J= 1.1 Hz, 1H), 7.79 (d, J= 7.8 Hz, 1H), 7.66 - 7.53 (m, 3H), 7.46 (d, J= 6.8 Hz, 1H), 6.57 (d, J= 9.1 Hz, 1H), 4.28 (s, 2H), 3.80 - 3.71 (m, 2H), 3.54 - 3.46 (m, 1H), 3.41 - 3.33 (m, 2H), 2.16 - 2.08 (m, 1H), 1.79 - 1.70 (m, 2H), 1.55 - 1.45 (m, 2H), 1.26 1.21 (m, 2H), 1.14 - 1.08 (m, 2H). Compound 21 was synthesized from VII-21 as the raw material according to the synthesis method of compound 1, white solid, yield 69%; IH NMR (400 MHz, DMSO) 6 8.46 (d, J= 2.1 Hz, 1H), 7.86 (d, J= 7.8 Hz, 1H), 7.81 - 7.72 (m, 2H), 7.68 (t, J= 7.6 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 6.85 (d, J= 9.2 Hz, 1H), 4.28 (s, 2H), 3.81 - 3.70 (m, 2H), 3.45 (s, 1H), 3.25
(t, J= 9.4 Hz, 2H), 2.33 - 2.23 (m, 1H), 1.75 - 1.61 (m, 2H), 1.38 - 1.25 (m,2H), 1.17 - 1.04 (m,4H). MS(ESI,m/z): 528 [M+H]+. Example 22:
0
N CF 3 HN 22 The synthetic route of example 22 was as follows.
Br IX-14 \ N~ CF3 CF 3 N CF3
V-8 VII-22 22
Compound intermediate VII-22 was synthesized from V-8 and IX-14 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 71 %; 'H NMR (400 MHz, CDC3) 68.23 (d, J= 2.7 Hz, 1H), 7.78 (d, J= 7.2 Hz, 1H), 7.62 - 7.53 (m, 2H), 7.49 7.43 (m, 2H), 7.03 (dd, J= 8.8, 2.7 Hz, 1H), 4.28 (s, 2H), 3.53 - 3.46 (m, 1H), 3.43 - 3.36 (m, 2H), 3.18 - 3.10 (m, 2H), 2.15 - 2.07 (m, 1H), 1.83 - 1.75 (m, 2H), 1.62 - 1.52 (m, 2H), 1.24 1.20 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 22 was synthesized from VII-22 as the raw material according to the synthesis method of compound 1, white solid, yield 66%; H NMR (400 MHz, DMSO) 6 8.33 (d, J= 2.3 Hz, 1H), 7.85 (d, J= 7.7 Hz, 1H), 7.78 - 7.64 (m, 3H), 7.59 (d, J= 7.5 Hz, 1H), 7.32 (dd, J= 9.0, 2.3 Hz, 1H), 4.29 (s, 2H), 3.50 - 3.36 (m, 3H), 3.06 (t, J= 9.1 Hz, 2H), 2.34 - 2.23 (m, 1H), 1.79 - 1.68 (m, 2H), 1.46 - 1.33 (m, 2H), 1.14 - 1.04 (m, 4H). MS(ESI,m/z): 528 [M+H]+. Example 23:
0CF N N' I F HN-0 23 The synthetic route of example 23 was as follows.
Br Ix1 F\F
SCF, * CF, .N I CF3 HN
V-8 VII-23 23 0
Compound intermediate VII-23 was synthesized from V-8 and IX-18 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 70%; 'H NMR (400 MHz, CDCl3) 6 7.84 - 7.79 (m, 1H), 7.66 - 7.56 (m, 2H), 7.49 (d, J= 6.8 Hz, 1H), 7.35 (dd, J = 8.4, 1.3 Hz, 1H), 7.28 - 7.24 (m, 1H), 6.87 (t, J= 8.4 Hz, 1H), 4.29 (s, 2H), 3.49 - 3.38 (m,
1H), 3.32 - 3.23 (m, 2H), 2.97 - 2.88 (m, 2H), 2.18 - 2.09 (m, 1H), 1.90 - 1.82 (m, 2H), 1.68 1.59 (m, 2H), 1.29 - 1.25 (m, 2H), 1.17 - 1.10 (m, 2H). Compound 23 was synthesized from VII-23 as the raw material according to the synthesis method of compound 1, white solid, yield 61%; 'H NMR (400 MHz, DMSO) 6 7.91 (d, J= 7.7 Hz, 1H), 7.83 - 7.70 (m, 2H), 7.60 (d, J= 7.5 Hz, 1H), 7.56 - 7.47 (m, 2H), 7.14 - 7.07 (m, 1H), 4.29 (s, 2H), 3.44 - 3.33 (m, 1H), 3.18 - 3.09 (m, 2H), 2.88 - 2.79 (m, 2H), 2.37 - 2.29 (m, 1H), 1.82 - 1.73 (m, 2H), 1.50 - 1.39 (m, 2H), 1.18 - 1.06 (m, 4H). MS(ESI,m/z): 545
[M+H]+. Example 24:
C N N "ICF 3 /' HN4 - 0 24
The synthetic route of example 24 was as follows.
0 o FBr C NN
HN, V-8 VII-23 23
Compound intermediate VII-24 was synthesized from V-8 and IX-16 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 70%; IH NMR (400 MHz, CDCl3) 6 7.82 - 7.75 (m, 1H), 7.64 - 7.54 (m, 2H), 7.47 - 7.43 (m, 1H), 7.38 - 7.31 (m, 1H), 6.57 (dd, J= 8.9, 2.4 Hz, 1H), 6.48 (dd, J= 13.3, 2.4 Hz, 1H), 4.28 (s, 2H), 3.52 - 3.45 (m, 1H), 3.43 - 3.34 (m, 2H), 3.15 - 3.04 (m, 2H), 2.16 - 2.07 (m, 1H), 1.83 - 1.72 (m, 2H), 1.59 - 1.49 (m, 2H), 1.25 - 1.20 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 24 was synthesized from VII-24 as the raw material according to the synthesis method of compound 1, white solid, yield 61%; IH NMR (400 MHz, DMSO) 6 7.89 (d, J= 7.7 Hz, 1H), 7.81- 7.68 (m, 2H), 7.59 (d, J= 7.5 Hz, 1H), 7.52 (t, J= 8.9 Hz, 1H), 6.85 (dd, J= 10.2, 7.5 Hz, 2H), 4.28 (s, 2H), 3.48 - 3.39 (m, 3H), 3.11 - 3.00 (m, 2H), 2.38 - 2.27 (m, 1H), 1.75 - 1.65 (m, 2H), 1.39 - 1.27 (mS, 2H), 1.17 - 1.05 (m, 4H). MS(ESI,m/z): 545 [M+H]+. Example 25:
N N, 0 "I CF 3 F 0 25
The synthetic route of example 25 was as follows.
oX1 ow Br IIF N.
CF CF 3 N CF N
V-8 Ff 11 F HN o VII-25 F 25 Compound intermediate VII-25 was synthesized from V-8 and IX-17 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 59%; 'H NMR (400 MHz, CDCl3) 6 7.79 - 7.76 (m, 1H), 7.64 - 7.54 (m, 2H), 7.47 - 7.43 (m, 1H), 6.30 (d, J= 11.7 Hz, 2H), 4.27 (s, 2H), 3.54 - 3.46 (m, 1H), 3.40 - 3.30 (m, 2H), 3.18 - 3.06 (m, 2H), 2.16 2.05 (m, 1H), 1.82 - 1.70 (m, 2H), 1.57 - 1.49 (m, 2H), 1.23 - 1.18 (m, 2H), 1.14 - 1.07 (m, 2H). Compound 25 was synthesized from VII-25 as the raw material according to the synthesis method of compound 1, white solid, yield 64%; 'H NMR (400 MHz, DMSO) 6 7.89 (d, J= 7.7 Hz, 1H), 7.80 - 7.68 (m, 2H), 7.60 (d, J= 7.4 Hz, 1H), 6.77 (d, J= 13.3 Hz, 2H), 4.29 (s, 2H), 3.50 - 3.38 (m, 3H), 3.18 - 3.03 (m, 2H), 2.37 - 2.25 (m, 1H), 1.78 - 1.64 (m, 2H), 1.43 1.27 (m, 2H), 1.20 - 1.03 (m, 4H). MS(ESI,m/z): 563 [M+H]+. Example 26:
OWN N SOCF3 HN4 I - HN4 0
21
The synthetic route of example 26 was as follows.
Br IX-13 OC N N N K/-N N \ N, OCF3, OCF 3 ZNI OCF 3 /HN0
V-9 VII-26 26 H 0
Compound intermediate VII-26 was synthesized from V-9 and IX-13 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 67%; 'H NMR (400 MHz, CDC3) 6 8.37 (s, 1H), 7.60 - 7.47 (m, 3H), 7.41 - 7.34 (m, 2H), 6.57 (d, J= 9.1 Hz, 1H), 4.41 (s, 2H), 3.85 - 3.73 (m, 2H), 3.60 - 3.50 (m, 1H), 3.43 - 3.32 (m, 2H), 2.19 - 2.09 (m, 1H), 1.81 - 1.73 (m, 2H), 1.57 - 1.47 (m, 2H), 1.25 - 1.20 (m, 2H), 1.14 - 1.07 (m, 2H).
Compound 26 was synthesized from VII-26 as the raw material according to the synthesis method of compound 1, white solid, yield 68%; 'H NMR (400 MHz, DMSO) 6 8.46 (d, J= 2.3 Hz, 1H), 7.80 (dd, J= 9.1, 2.3 Hz, 1H), 7.69 - 7.61 (m, 2H), 7.57 - 7.49 (m, 2H), 6.92 (d, J= 9.2 Hz, 1H), 4.38 (s, 2H), 3.88 - 3.75 (m, 2H), 3.57 - 3.47 (m, 1H), 3.32 - 3.21 (m, 2H), 2.37 - 2.27 (m, 1H), 1.77 - 1.67 (m, 2H), 1.38 - 1.27 (m, 2H), 1.16 - 1.05 (m, 4H). MS(ESI,m/z): 544 [M+H]+. Example 27:
0
OCF 3 N N'O I - ,,HN4 0 27 The synthetic route of example 27 was as follows.
o O Br IX-14 NN N -N OCF3 OCF, N OCF3 N -N HN$ -' 27 V-9 VII-27
Compound intermediate VII-27 was synthesized from V-9 and IX-14 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 74%; IH NMR (400 MHz, CDC3) 6 8.23 (s, 1H), 7.58 - 7.43 (m, 3H), 7.37 (d, J= 7.8 Hz, 2H), 7.03 (dd, J= 8.8, 2.7 Hz, 1H), 4.40 (s, 2H), 3.57 - 3.50 (m, 1H), 3.48 - 3.38 (m, 2H), 3.19 - 3.09 (m, 2H), 2.17 - 2.08 (m, 1H), 1.87 - 1.75 (m, 2H), 1.65 - 1.54 (m, 2H), 1.24 - 1.18 (m, 2H), 1.13 - 1.07 (m, 2H). Compound 27 was synthesized from VII-27 as the raw material according to the synthesis method of compound 1, white solid, yield 61%; 'H NMR (400 MHz, DMSO) 6 8.34 (d, J= 2.4 Hz, 1H), 7.71 (d, J= 8.9 Hz, 1H), 7.67 - 7.58 (m, 2H), 7.52 - 7.46 (m, 2H), 7.33 (dd, J= 8.9, 2.1 Hz, 1H), 4.38 (s, 2H), 3.56 - 3.42 (m, 3H), 3.07 (t, J= 9.3 Hz, 2H), 2.34 - 2.23 (m, 1H), 1.83 - 1.72 (m, 2H), 1.49 - 1.37 (m, 2H), 1.14 - 1.03 (m, 4H). MS(ESI,m/z): 544 [M+H]+. Example 28:
0 O CoF N F N'O I HN 0 28
The synthetic route of example 28 was as follows.
Br IX-18 O F O N F N OCF 3 N OCF 3 / N OCF3 / /0'
28 HN40 VII-28 V-9
Compound intermediate VII-28 was synthesized from V-9 and IX-18 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 67%; 'H NMR (400 MHz, CDCl3) 6 7.60 - 7.56 (m, 1H), 7.55 - 7.49 (m, 1H), 7.41 - 7.37 (m, 2H), 7.33 (d, J= 8.4
Hz, 1H), 7.25 (d, J= 12.7 Hz, 1H), 6.87 (t, J= 8.6 Hz, 1H), 4.41 (s, 2H), 3.51 - 3.42 (m, 1H), 3.34 - 3.23 (m, 2H), 2.97 - 2.88 (m, 2H), 2.20 - 2.11 (m, 1H), 1.91 - 1.82 (m, 2H), 1.70 - 1.59 (m, 2H), 1.25 - 1.22 (m, 2H), 1.15 - 1.08 (m, 2H). Compound 28 was synthesized from VII-28 as the raw material according to the synthesis method of compound 1, white solid, yield 72%; 'H NMR (400 MHz, DMSO) 6 7.69 - 7.62 (m, 2H), 7.57 - 7.46 (m, 4H), 7.10 (t, J= 8.7 Hz, 1H), 4.37 (s, 2H), 3.48 - 3.40 (m, 1H), 3.24 3.11 (m, 2H), 2.85 (t, J= 9.2 Hz, 2H), 2.40 - 2.25 (m, 1H), 1.87 - 1.75 (m, 2H), 1.56 - 1.40 (m, 2H), 1.16 - 1.04 (m, 4H). MS(ESI,m/z): 561 [M+H]+. Example 29:
NC OCF3 N NO I ) HN-$ 29 The synthetic route of example 29 was as follows.
Br \ 0P - F
N OCF 3 X6 OCF N N OCF3 N
/ V-9 VII-29 29
Compound intermediate VII-29 was synthesized from V-9 and IX-16 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 72%; 1H NMR (400 MHz, CDCl3) 6 7.57 - 7.47 (m, 2H), 7.41 - 7.30 (m, 3H), 6.57 (dd, J= 8.9, 2.4 Hz, 1H), 6.48 (dd, J= 13.3, 2.4 Hz, 1H), 4.40 (s, 2H), 3.57 - 3.49 (m, 1H), 3.46 - 3.37 (m, 2H), 3.15 - 3.05 (m, 2H), 2.17 - 2.09 (m, 1H), 1.84 - 1.74 (m, 2H), 1.60 - 1.50 (m, 2H), 1.23 - 1.18 (m, 2H), 1.13 - 1.06 (m, 2H). Compound 29 was synthesized from VII-29 as the raw material according to the synthesis method of compound 1, white solid, yield 60%; 'H NMR (400 MHz, DMSO) 6 7.69 - 7.61 (m, 2H), 7.58 - 7.48 (m, 3H), 6.91 - 6.80 (m, 2H), 4.38 (s, 2H), 3.55 - 3.43 (m, 3H), 3.14 - 2.99 (m, 2H), 2.37 - 2.27 (m, 1H), 1.79 - 1.66 (m, 2H), 1.43 - 1.30 (m, 2H), 1.18- 1.03 (m, 4H). MS(ESI,m/z): 561 [M+H]+. Example 30:
O\ o-~C F
2NOCF3 N
30 F N\\
The synthetic route of example 30 was as follows.
0 o Br IX-17 N ON x N OF N, OCF3 OCF3 / N OCF3 N0 11-0 HN-4 V-9 Vll-30 F 30 F 0
Compound intermediate VII-30 was synthesized from V-9 and IX-17 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 62%; IH NMR (400 MHz, CDC3) 6 7.57 - 7.49 (m, 2H), 7.42 - 7.35 (m, 2H), 6.31 (d, J= 11.6 Hz, 2H), 4.41 (s, 2H), 3.59 - 3.51 (m, 1H), 3.42 - 3.34 (m, 2H), 3.19 - 3.08 (m, 2H), 2.17 - 2.09 (m, 1H), 1.82 1.73 (m, 2H), 1.61 - 1.51 (m, 2H), 1.24 - 1.20 (m, 2H), 1.14 - 1.08 (m, 2H). Compound 30 was synthesized from VII-30 as the raw material according to the synthesis method of compound 1, white solid, yield 64%; IH NMR (400 MHz, DMSO) 6 7.69 - 7.62 (m, 2H), 7.57 - 7.49 (m, 2H), 6.79 (d, J= 13.3 Hz, 2H), 4.38 (s, 2H), 3.57 - 3.45 (m, 3H), 3.17 3.06 (m, 2H), 2.40 - 2.25 (m, 1H), 1.82 - 1.66 (m, 2H), 1.44 - 1.28 (m, 2H), 1.19- 1.02 (m, 4H). MS(ESI,m/z): 579 [M+H]+. Example 31:
31 The synthetic route of example 31 was as follows. HOer \ F N-HO-..-( N~ HO NH + F CN H N -/CN IX-31
000 ,\ 0 \Br F_ F NIX-13 F F F F
11-31 IV-31 V-31
0 0 N -- r N N
F F N CN F F HN40 VII-31 31 Compound intermediate IX-31 was synthesized from nortropine as the raw material according to the synthesis method of compound IX-10, white solid, yield 94%; 'H NMR (400 MHz, CDC3) 68.41 (d, J= 1.8 Hz, 1H), 7.58 (dd, J= 9.0, 2.3 Hz, 1H), 6.49 (d, J= 8.9 Hz, 1H), 4.91 - 4.26 (m, 2H), 4.12 (t, J= 4.7 Hz, 1H), 2.39 (d, J= 7.3 Hz, 2H), 2.18 - 2.04 (m, 4H), 1.81 (d, J= 14.3 Hz, 2H); Compound V-31 was synthesized from 11-31 as the raw material according to the synthesis method of compound 10, wherein, IV-31, white solid, yield 64%. H NMR (400 MHz, CDCl3) 6 7.43 - 7.34 (m, 1H), 7.00 - 6.91 (m, 2H), 3.69 (s, 3H), 2.92 - 2.83 (m, 1H), 1.36 - 1.31 (m, 2H), 1.25 - 1.20 (m, 2H). V-31, colourless liquid, yield 82%. 'H NMR (400 MHz, CDCl3) 6 7.54 - 7.44 (m, 1H), 7.11 7.04 (m, 2H), 4.33 (s, 2H), 2.20 - 2.08 (m, 1H), 1.34 - 1.17 (m, 4H). Compound intermediate VII-31 was synthesized from V-31 and IX-13 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 55%. 1H NMR (400 MHz, CDC3) 68.36 (d, J= 2.1 Hz, 1H), 7.53 (dd, J= 9.0,2.1 Hz, 1H), 7.49 - 6.39 (m, 1H), 7.07 - 6.96 (m, 2H), 6.42 (d, J= 9.0 Hz, 1H), 4.75 - 4.18 (m, 4H), 3.48 (t, J= 4.5 Hz, 1H), 2.16 - 2.08 (m, 1H), 1.99 - 1.92 (m, 2H), 1.90 - 1.81 (m, 4H), 1.69 (d, J= 14.5 Hz, 2H), 1.25 - 1.20 (m, 2H), 1.14 - 1.08 (m, 2H). Compound 31 was synthesized from VII-31 as the raw material according to the synthesis method of compound 1, white solid, yield 76%.1 H NMR (400 MHz, DMSO) 6 8.46 (d, J= 2.3 Hz, 1H), 7.78 (dd, J= 9.0, 2.3 Hz, 1H), 7.70 - 7.59 (m, 1H), 7.29 (t, J= 8.0 Hz, 2H), 6.76 (d, J= 9.0 Hz, 1H), 4.41 (s, 2H), 4.31 (s, 2H), 3.45 (s, 1H), 2.39 - 2.26 (m, 1H), 1.86 - 1.68 (m, 6H), 1.59 (d, J= 14.4 Hz, 2H), 1.19 - 1.03 (m, 4H). MS(ESI,m/z): 522[M+H]+. Example 32: ci ci 00 1 NN' HN,
32
The synthetic route of example 32 was as follows.
N Br O\ o/ IX-31 N C N'O CI ci c ci /CN ci ci
' HN 40 V-1 VII-32 32 Compound intermediate VII-32 was synthesized from V- Iand IX-31 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 69%; 1 H NMR (400 MHz, CDC 3) 68.34 (d, J= 2.1 Hz, 1H), 7.51 (dd, J= 9.0, 2.1 Hz, 1H), 7.42 - 7.38 (m, 2H), 7.36 - 7.30 (m, 1H), 6.41 (d, J= 9.0 Hz, 1H), 4.63 - 4.16 (m, 4H), 3.46 (t, J= 4.3 Hz, 1H), 2.15 - 2.07 (m, 1H), 1.97 - 1.91 (m, 2H), 1.88 - 1.78 (m, 4H), 1.70 (d, J= 14.5 Hz, 2H), 1.25 - 1.21 (m, 2H), 1.14 - 1.07 (m, 2H). Compound 32 was synthesized from VII-32 as the raw material according to the synthesis method of compound 1, white solid, yield 68%; 1H NMR (400 MHz, DMSO) 6 8.45 (d, J= 2.3 Hz, 1H), 7.78 (dd, J= 9.0, 2.3 Hz, 1H), 7.68 - 7.60 (m, 2H), 7.59 - 7.53 (m, 1H), 6.77 (d, J= 9.1 Hz, 1H), 4.41 (s, 2H), 4.26 (s, 2H), 3.43 (s, 1H), 2.38 - 2.28 (m, 1H), 1.86 - 1.54 (m, 8H), 1.18 - 1.05 (m, 4H). MS(ESI,m/z): 554 [M+H]+. Example 33:
NCF3 N ,N'O HN 33 The synthetic route of example 33 was as follows.
Br I P 0-" NN N 0 CF CF N 3 C3C N' SCF, HN4
V-8 VII-33 33 Compound intermediate VII-33 was synthesized from V-8 and IX-31 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 73%; IH NMR (400 MHz, CDC3) 68.32 (d, J= 2.1 Hz, 1H), 7.76 (d, J= 7.3 Hz, 1H), 7.63 - 7.53 (m, 2H), 7.49 (dd, J= 9.0, 2.1 Hz, 1H), 7.44 - 7.40 (m, 1H), 6.39 (d, J= 9.0 Hz, 1H), 4.57 - 4.12 (m, 4H), 3.42 (t, J= 4.3 Hz, 1H), 2.13 - 2.04 (m, 1H), 1.98 - 1.91 (m, 2H), 1.88 - 1.78 (m, 4H), 1.69 (d, J= 14.6 Hz, 2H), 1.20 - 1.15 (m, 2H), 1.11 - 1.05 (m, 2H). Compound 33 was synthesized from VII-33 as the raw material according to the synthesis method of compound 1, white solid, yield 51%; 'H NMR (400 MHz, DMSO) 6 8.45 (d, J= 2.3 Hz, 1H), 7.92 (d, J= 7.4 Hz, 1H), 7.84 - 7.72 (m, 3H), 7.60 (d, J= 7.4 Hz, 1H), 6.79 (d, J = 9.1 Hz, 1H), 4.19 (s, 2H), 4.23 (s, 2H), 3.43 (s, 1H), 2.37 - 2.28 (m, 1H), 1.82 - 1.69 (m,
6H), 1.62 (d, J= 14.4 Hz, 2H), 1.17 - 1.05 (m, 4H). MS(ESI,m/z): 554 [M+H]+. Example 34:
0 OC N N' -~OCF 3 HN, /
34 The synthetic route of example 34 was as follows.
Br I o /
N N. OCF 3 OCF, N /CN OCF 3 HN X 40 V-9 VII-34 34 Compound intermediate VII-34 was synthesized from V-9 and IX-31 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 76%; IH NMR (400 MHz, CDC3) 6 8.35 (d, J= 2.1 Hz, 1H), 7.58 - 7.47 (m, 3H), 7.40 - 7.35 (m, 2H), 6.44 - 6.38 (m, 1H), 4.57 - 4.23 (m, 4H), 3.48 (t, J= 4.5 Hz, 1H), 7.16 - 2.06 (m, 1H), 1.98 - 1.92 (m, 2H), 1.90 - 1.82 (m, 4H), 1.70 (d, J= 14.5 Hz, 2H), 1.22 - 1.18 (m, 2H), 1.13 - 1.07 (m, 2H). Compound 34 was synthesized from VII-34 as the raw material according to the synthesis method of compound 1, white solid, yield 66%; IH NMR (400 MHz, DMSO) 6 8.47 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 9.0, 2.3 Hz, 1H), 7.69 - 7.59 (m, 2H), 7.56 - 7.49 (m, 2H), 6.75 (d, J= 9.1 Hz, 1H), 4.41 (s, 2H), 4.32 (s, 2H), 3.47 (s, 1H), 2.35 - 2.26 (m, 1H), 1.86 - 1.68 (m, 6H), 1.63 (d, J= 14.4 Hz, 2H), 1.15 - 1.02 (m, 4H). MS(ESI,m/z): 570 [M+H]+. Example 35:
0F
F F HN4 35 The synthetic route of example 35 was as follows.
F F ~HO,/F H+ F HO N+ CN
IX-35
0 0 N\ Br IX-35 ,\~F N N. F
F F B F O N CN F F N N HN'4.
V-31 VII-35 K-0 35 Compound intermediate IX-35 was synthesized from nortropine as the raw material according to the synthesis method of compound IX-10, white solid, yield 64%; 'H NMR (400 MHz, CDCl3) 6 7.42 - 7.34 (m, 1H), 6.48 (dd, J= 8.8, 2.3 Hz, 1H), 6.41 (dd, J= 12.8, 2.3 Hz, 1H), 4.21 (s, 2H), 4.09 (t, J= 4.4 Hz, 1H), 2.44 - 2.36 (m, 2H), 2.18 - 2.05 (m, 4H), 1.74 (d, J= 13.9 Hz, 2H), 1.66 1.59 (m, 1H); Compound intermediate VII-35 was synthesized from V-31 and IX-35 as the raw materials accordingto the synthesis method of compoundVII-10, white solid, yield 79%; 1HNMR(400 MHz, CDCl3) 6 7.49 - 7.41 (m, 1H), 7.37 - 7.30 (m, 1H), 7.07 - 7.00 (m, 2H), 6.44 - 7.31 (m, 2H), 4.31 (s, 2H), 4.06 (s, 2H), 3.46 (t, J= 4.5 Hz, 1H), 2.16 - 2.08 (m, 1H), 1.99 - 1.92 (m, 2H), 1.91 - 1.82 (m, 4H), 1.63 (d, J= 14.5 Hz, 2H), 1.25 - 1.20 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 35 was synthesized from VII-35 as the raw material according to the synthesis method of compound 1. White solid, yield 66%; 1H NMR (400 MHz, DMSO) 6 7.70 - 7.59 (m, 1H), 7.50 (t, J= 8.6 Hz, 1H), 7.29 (t, J= 8.0 Hz, 2H), 6.76 - 6.64 (m, 2H), 4.31 (s, 2H), 4.17 (s, 2H), 3.43 (s, 1H), 2.37 - 2.26 (m, 1H), 1.83 - 1.67 (m, 6H), 1.52 (d, J= 14.5 Hz, 2H), 1.16 - 1.04 (m, 4H). MS(ESI,m/z): 539 [M+H]+. Example 36:
0F
ciN N CIO '
36 The synthetic route of example 36 was as follows.
cl cir Cl N l CIO NCN C1 CIO N N'O HN 0 V-1 VII-36 36 Compound intermediate VII-36 was synthesized from V- Iand IX-35 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 73%; H NMR (400 MHz, CDCl3) 6 7.46 - 7.41 (m, 2H), 7.39 - 7.31 (m, 2H), 6.42 (dd, J= 8.8, 2.1 Hz, 1H), 6.35 (d, J= 12.8 Hz, 1H), 4.26 (s, 2H), 4.07 (s, 2H), 3.46 (t,J= 4.4 Hz, 1H), 2.17 - 2.08 (m, 1H), 2.01 - 1.95 (m, 2H), 1.91 - 1.82 (m, 4H), 1.66 (d, J= 14.7 Hz, 2H), 1.29 - 1.24 (m, 2H), 1.17 - 1.10 (m, 2H). Compound 36 was synthesized from VII-36 as the raw material according to the synthesis method of compound 1, white solid, yield 65%; IH NMR (400 MHz, DMSO) 6 7.65 - 7.59 (m, 2H), 7.58 - 7.47 (m, 2H), 6.69 (t, J= 12.8 Hz, 2H), 4.25 (s, 2H), 4.17 (s, 2H), 3.41 (s, 1H), 2.38 - 2.27 (m, 1H), 1.8. - 1.68 (m, 6H), 1.54 (d, J= 14.5 Hz, 2H), 1.17- 1.05 (m, 4H). MS(ESI,m/z): 571 [M+H]+. Example 37:
C. FF N CF3 N ,N'O HN 37 The synthetic route of example 37 was as follows.
Br I \ o
CF 3 NCF N CN CF 3 N HN4
V-8 VII-37 37
Compound intermediate VII-37 was synthesized from V-8 and IX-35 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 74%; 'H NMR (400 MHz, CDCl3) 6 7.84 - 7.79 (m, 1H), 7.67 - 7.58 (m, 2H), 7.48 - 7.42 (m, 1H), 7.39 - 7.32 (m, 1H), 6.45 - 6.31 (m, 2H), 4.20 (s, 2H), 4.08 (s, 2H), 3.43 (s, 1H), 2.14 - 2.07 (m, 1H), 2.02 1.95 (m, 2H), 1.94 - 1.83 (m, 4H), 1.66 (d, J= 14.7 Hz, 2H), 1.29 - 1.23 (m, 2H), 1.16 - 1.09 (m, 2H). Compound 37 was synthesized from VII-37 as the raw material according to the synthesis method of compound 1, white solid, yield 61%; 'H NMR (400 MHz, DMSO) 6 7.91 (d, J= 7.6 Hz, 1H), 7.83 - 7.70 (m, 2H), 7.60 (d, J= 7.4 Hz, 1H), 7.50 (t, J= 8.6 Hz, 1H), 6.75 - 6.64 (m, 2H), 4.26 - 4.13 (m, 4H), 3.40 (s, 1H), 2.38 - 2.24 (m, 1H), 1.83 - 1.69 (m, 6H), 1.55 (d, J = 14.5 Hz, 2H), 1.18 - 1.03 (m, 4H). MS(ESI,m/z): 571 [M+H]+.
Example 38:
N" -N N /( , 0 OCF, N'O HN--\ 38 The synthetic route of example 38 was as follows.
Br I 0-- C F a ~ FN,. F\ OCF 3 OCF3 N_, CNOC NN'0 HN 0 V-9 VIl-38 38 Compound intermediate VII-38 was synthesized from V-9 and IX-35 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 74%; 'H NMR (400 MHz, CDCl3 ) 6 7.58 - 7.50 (m, 2H), 7.43 - 7.37 (m, 2H), 7.34 (t, J= 8.2 Hz, 1H), 6.42 (dd, J = 8.8, 2.2 Hz, 1H), 6.35 (dd, J= 12.8, 2.2 Hz, 1H), 4.34 (s, 2H), 4.06 (s, 2H), 3.47 (t, J= 4.5
Hz, 1H), 2.16 - 2.07 (m, 1H), 2.00 - 1.94 (m, 2H), 1.92 - 1.84 (m, 4H), 1.64 (d, J= 14.5 Hz, 2H), 1.26 - 1.20 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 38 was synthesized from VII-38 as the raw material according to the synthesis method of compound 1, white solid, yield 67%; 1 H NMR (400 MHz, DMSO) 6 7.71 - 7.60 (m, 2H), 7.58 - 7.46 (m, 3H), 6.77 - 6.64 (m, 2H), 4.32 (s, 2H), 4.19 (s, 2H), 3.45 (s, 1H), 2.37 2.27 (m, 1H), 1.86 - 1.69 (m, 6H), 1.56 (d,J= 14.5 Hz, 2H), 1.17 - 1.04 (m, 4H). MS(ESI,m/z): 587 [M+H]+. Example 39:
SOCFH N/' HN 39 The synthetic route of example 39 was as follows.
0 0
OCF 2H N Br IX-31 HF 2CO HF2 CO 10
11-39 IV-39 V-39
OCFH N CN OCF2 H HN\0 VII-9 V
Compound V-39 was synthesized from 11-39 as the raw material according to the synthesis method of compound 10, wherein, IV-39, white solid, yield 54%. H NMR (400 MHz, CDCl3) 6 7.52 - 7.44 (m, 2H), 7.32 - 7.26 (m, 1H), 7.21 (d, J= 8.5 Hz, 1H), 6.46 (t, J= 73.7 Hz, 1H), 3.72 (s, 3H), 2.88 - 2.80 (m, 1H), 1.37 - 1.32 (m, 2H), 1.26 - 1.22 (m, 2H). V-39, colourless liquid, yield 72%. IH NMR (400 MHz, CDCl3) 6 7.60 - 7.51 (m, 2H), 7.41 7.32 (m, 2H), 6.51 (t, J= 73.7 Hz, 1H), 4.38 (s, 2H), 2.18 - 2.10 (m, 1H), 1.32 - 1.17 (m, 4H). Compound intermediate VII-39 was synthesized from V-39 and IX-31 as the raw materials according to the synthesis method of compound VI-10, white solid, yield 6 1 %. 'H NMR (400 MHz, CDC3) 6 8.37 (d, J= 2.2 Hz, 1H), 7.57 - 7.45 (m, 3H), 7.35 - 7.24 (m, 2H), 6.47 (t, J= 74.1 Hz, 1H), 6.42 (d, J= 8.9 Hz, 1H), 4.34 (s, 4H), 3.49 (t, J= 4.5 Hz, 1H), 2.16 - 2.08 (m, 1H), 2.00 - 1.94 (m, 2H), 1.90 - 1.82 (m, 4H), 1.72 (d, J= 14.4 Hz, 2H), 1.23 - 1.20 (m, 2H), 1.14 - 1.07 (m, 2H). Compound 39 was synthesized from VII-39 as the raw material according to the synthesis method of compound 1, white solid, yield 78%. H NMR (400 MHz, DMSO) 6 8.46 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 9.0, 2.3 Hz, 1H), 7.64 - 7.55 (m, 1H), 7.54 - 7.49 (m, 1H), 7.40 - 7.33 (m, 2H), 7.23 (d, J= 73.6 Hz, 1H), 6.77 (d, J= 9.0 Hz, 1H), 4.55 - 4.23 (m, 4H), 3.46 (s, 1H), 2.36 - 2.27 (m, 1H), 1.86- 1.69 (m, 6H), 1.62 (d, J= 14.4 Hz, 2H), 1.15- 1.05 (m, 4H). MS(ESI,m/z): 552[M+H]+. Example 40:
040 HN 400
The synthetic route of example 40 was as follows.
o0 0 ,\ 0 NN.. N Br IX-31
11-40 IV-40 V-40
0 N N N N HN-0 VII-40 40 Compound V-40 was synthesized from 11-40 as the raw material according to the synthesis method of compound 10, wherein,
IV-40, white solid, yield 54%. 1H NMR (400 MHz, CDCl3) 6 7.42 - 7.31 (m, 2H), 7.30 - 7.24 (m, 2H), 3.69 (s, 3H), 2.95 - 2.87 (m, 1H), 2.23 (s, 3H), 1.42 - 1.36 (m, 2H), 1.30 - 1.23 (m, 2H). V-40, colourless liquid, yield 72%. 1H NMR (400 MHz, CDC3) 6 7.42 - 7.29 (m, 4H), 4.27 (s, 2H), 2.33 (s, 3H), 2.19 - 2.10 (m, 1H), 1.32 - 1.27 (m, 2H), 1.23 - 1.16 (m, 2H). Compound intermediate VII-40 was synthesized from V-40 and IX-31 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 6 1 %. 1H NMR (400 MHz, CDC3) 6 8.37 (d, J= 1.8 Hz, 1H), 7.54 (dd, J= 8.8, 2.3 Hz, 1H), 7.37 - 7.22 (m, 4H), 6.43 (d, J= 8.8 Hz, 1H), 4.76 - 4.30 (m, 2H), 4.20 (s, 2H), 3.49 (t, J= 4.4 Hz, 1H), 2.30 (s, 3H), 2.16 - 2.10 (m, 1H), 2.07 - 2.02 (m, 2H), 1.93 - 1.83 (m, 4H), 1.77 (d, J= 14.3 Hz, 2H), 1.26 - 1.21 (m, 2H), 1.15 1.08 (m, 2H). Compound 40 was synthesized from VII-40 as the raw material according to the synthesis method of compound 1, white solid, yield 78%. 1H NMR (400 MHz, DMSO) 6 8.47 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 9.0,2.3 Hz, 1H), 7.39 - 7.24 (m, 4H), 6.75 (d, J= 9.0 Hz, 1H), 4.43 (s, 2H), 4.19 (s, 2H), 3.45 (s, 1H), 2.33 - 2.24 (m, 1H), 2.21 (s, 3H), 1.92 - 1.64 (m, 8H), 1.13 - 1.04 (m, 4H). MS(ESI,m/z): 500[M+H]+. Example 41:
N OCFH N HN40 41 The synthetic route of example 41 was as follows.
'\ Br 0F F
HF 2CO N \ OCF 2H N CN OCF 2H HN-40
V-39 VII-41 41
Compound intermediate VII-41 was synthesized from V-41 and IX-35 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 64%. 1 H NMR (400 MHz, CDCl3) 6 7.55 - 7.48 (m, 2H), 7.38 - 7.29 (m, 3H), 6.47 (t, J= 74.1 Hz, 1H), 6.45 - 6.40 (m, 1H), 6.38 - 6.32 (m, 1H), 4.34 (s, 2H), 4.10 - 4.03 (m, 2H), 3.52 - 3.44 (m, 1H), 2.16 - 2.09 (m, 1H), 2.00 - 1.95 (m, 2H), 1.92 - 1.85 (m, 4H), 1.65 (d, J= 15.2 Hz, 2H), 1.25 - 1.22 (m, 2H), 1.15 - 1.09 (m, 2H). Compound 39 was synthesized from VII-39 as the raw material according to the synthesis method of compound 1, white solid, yield 7 1 %. 1H NMR (400 MHz, DMSO) 6 7.60 (td, J= 8.3, 1.7 Hz, 1H), 7.54 - 7.46 (m, 2H), 7.40 - 7.34 (m, 2H), 7.23 (t, J= 73.6 Hz, 1H), 6.78 6.62 (m, 2H), 4.32 (s, 2H), 4.18 (s, 2H), 3.43 (s, 1H), 2.37 - 2.27 (m, 1H), 1.86 - 1.69 (m, 6H), 1.55 (d, J= 14.5 Hz, 2H), 1.17 - 1.02 (m, 4H). MS(ESI,m/z): 569[M+H]+. Example 42:
N O N N'O HN4 42 The synthetic route of example 42 was as follows.
P\ Br F 0O\ <~
IX-35 NN N N N
HN V-40 VII-42 42
Compound intermediate VII-42 was synthesized from V-40 and IX-35 as the raw materials according to the synthesis method of compound VII-10, white solid, yield 49%. 1 H NMR (400 MHz, CDCl3) 6 7.28 - 7.23 (m, 2H), 7.33 - 7.29 (m, 2H), 7.28 - 7.23 (m, 1H), 6.46 - 6.41 (m, 1H), 6.39 - 6.34 (m, 1H), 4.21 (s, 2H), 4.13 - 4.06 (m, 2H), 3.50 - 3.43 (m, 1H), 2.31 (s, 3H), 2.07 (s, 3H), 1.97 - 1.86 (m, 4H), 1.75 - 1.67 (m, 2H), 1.29 - 1.23 (m, 2H), 1.16 - 1.09 (m, 2H). Compound 40 was synthesized from VII-40 as the raw material according to the synthesis method of compound 1, white solid, yield 61%. 1H NMR (400 MHz, CDCl3) 6 7.66 (t, J= 8.7 Hz, 1H), 7.37 - 7.22 (m, 4H), 6.52 (dd, J= 9.0, 1.9 Hz, 1H), 6.39 (dd, J= 14.9, 1.9 Hz, 1H), 4.20 (s, 2H), 4.09 (s, 2H), 3.49 - 3.43 (m, 1H), 2.30 (s, 3H), 2.17 - 2.01 (m, 3H), 1.92 (dd, J= 9.6, 3.4 Hz, 4H), 1.69 (d, J = 14.5 Hz, 2H), 1.28 - 1.20 (m, 2H), 1.17 - 1.08 (m, 2H). MS(ESI,m/z): 517[M+H]+. Examples of pharmacological experiments Test method for FXR activity at the molecular level FXR activity was determined using recombinant GST-FXR fusion protein by Perkin Elmer's AlphaScreen detection reagent. The reaction in this method was carried out in a 384 well plate, and the total reaction volume was 15 pL. The mixture of protein, agonist, co regulatory factor, AlphaScreen@ acceptor beads and AlphaScreen@ donor beads was reacted in abuffer containing Tris-HCl50 mM (pH7.4),50 mMNaCl, BSA 0.1%, and1mM DTT. The FXR activity was reflected by the fluorescence signal intensity at 570nm wavelength detected by the Envision fluorescence detector. The value of EC50 was calculated by the software Graphpad Prism 5. Test method for FXR activity at the cell level The FXR expression plasmid and FXRE luciferase reporter plasmid at a ratio of 1:9 was co-transfected into 293T cells, and then the transfected cells were seeded on a 96-well flat bottom microplate (ViewPlate-96, White 96- well Microplate with Clear Bottom, PerkinElmer) at 5x10 5/well. The cells were cultured for 24 hours to ensure plasmid expression. Then the FXR receptor agonist to be tested was added and acted for 18 hours. The fluorescence intensity was detected using luciferase kit (steady-Glo Luciferase Assay system) to reflect the compound's activation efficiency on the FXR receptor. CH
O 4 0
0
HOH 0 C1 0
OCA GW4064 In the preliminary screening, the test compound and the two positive compounds OCA, GW4064 acted on the cells at 10 tM, and the relative activities of the test compound to the two positive compounds were determined respectively (relative activity = (signal intensity of test compound -blank)/(signal intensity of positive compound -blank)x100%). The compound whose relative activity is higher than 50% of the positive compound enters the re-screening. The appropriate concentration interval was selected, and the dose-dependent relationship, that is, the EC50 value, was calculated. Table 1 Activity test results FXR activity at the FXR activity at the cell level molecular level Test sample EC5o (pM) Activity relative EC5o (pM) to OCA (%) 10pgM OCA 0.374 100 1.16 GW4064 0.98 106 0.024 Example 1(LXF-32) 0.446 109 0.11 Example 2(LXF-73) 0.072 174 0.001 Example 3(LXF-114) 1.81 82 0.014 Example 4(LXF-I11) 0.015 97 0.0006 Example 5(LXF-115) 4.70 83 0.844 Example 6(LXF-112) 3.92 99 0.032 Example 7(LXF-113) 0.0067 88 0.006 Example 8(Compound 8) 0.104 88 0.005 Example 9(LXF-117) 0.055 90 0.004 Example I0(LXF-128) 1.04 202 0.0002 Example I1(LXF-129) 0.439 164 0.0007 Example 12(LXF-130) 2.882 63 0.035 Example 13(LXF-131) 0.178 111 0.0007 Example 14(LXF-132) 0.598 74 0.005 Example 15(LXF-133) 2.653 159 0.003 Example 16(LXF-134) 0.195 168 0.0002 Example 17(LXF-135) 0.257 161 0.0003 Example 18(LXF-143) 0.614 150 0.002 Example 19(LXF-136) 3.138 132 0.285 Example 20(LXF-138) 5.471 146 0.005 Example 21 0.0967 117 0.00132
Example 22 0.386 108 0.00199 Example 23 0.392 109 0.00222 Example 24 0.0590 105 0.000196 Example 25 0.0847 103 0.00012 Example 26 0.0700 103 0.000254 Example 27 0.0209 106 0.000357 Example 28 0.380 107 0.000617 Example 29 0.108 120 0.000938 Example 30 0.0890 120 0.000255 Example 31 0.0113 116 0.000608 Example 32 0.00433 103 0.0000783 Example 33 0.0188 141 0.000387 Example 34 0.0197 122 0.000388 Example 35 0.0185 117 0.000318 Example 36 0.00422 102 0.0000317 Example 37 0.0506 102 0.000284 Example 38 0.0513 102 0.000304 Example 39 0.0250 108 0.00149 Example 40 0.0944 105 0.00211 Example 41 0.0285 108 0.000718 Example 42 0.0804 106 0.000960
Conclusion: The test results show that the compounds of the present invention have good agonistic ability to FXR at the molecular level and the cell level, and the activities of several compounds are significantly better than those of the two positive controls. In vivo pharmacological activity test of liver fibrosis 1) Pharmacodynamic evaluation of compound 1 (LXF-32) on TAA-induced hepatic fibrosis model rats In this experiment, TAA induced hepatic fibrosis model rats were used to investigate the effect of long-term oral administration of compound 1 on hepatic fibrosis in the model rats. Experimental method: Male SD rats were intraperitoneally injected with thioacetamide (TAA, dissolved in normal saline) at a dose of 150 mg/kg three times a week to induce a liver fibrosis model. Four weeks after the model was made, the blood was taken from the retro ocular venous plexus of the rats to detect serum ALP indicators. According to indicators such as ALP and body weight, the rats were randomly divided into 3 groups, each with 8 rats, which were respectively the model control group (Vehicle), Compound 1 group (20 mg/kg), positive compound OCA group (20 mg/kg), etc., orally administered by gavage, once a day. During the administration period, the animal's food intake and body weight were monitored. After 2 weeks of administration, the blood was taken from the retro-ocular venous plexus of the rats to detect serum ALP indicators. After 4 weeks of administration, the blood was taken from the retro-ocular venous plexus and the rats were dislocated and sacrificed. The livers were taken out and weighed. Part of the liver was fixed with 4% paraformaldehyde, and part of the liver was frozen at -80°C. During the whole experiment, another 8 rats in the same cage were injected intraperitoneally with the same volume of normal saline as the system normal control group (WT). This experiment detected indicators such as the level of liver function index ALP in serum, the expression of a-SMA and Collal (fibrosis-related genes) gene level in the liver, the content of hydroxyproline (a characteristic amino acid of collagen) in the liver, and the pathological changes of the liver (Sirius scarlet stain), etc., thereby reflecting whether the compound has the effect of relieving liver fibrosis. The research results showed that the compound 1 of the present invention significantly reduced the level of ALP in serum, reduced the content of hydroxyproline in liver tissue, and significantly down-regulated the expression of a-SMA and Collal mRNA in liver tissue after 4 weeks of administration (Figure 1). In the quantitative analysis of liver pathological sections stained with Sirius Scarlet, compound 1 reduced the collagen content in the liver, because there were large differences within the model group, and there was no statistical difference (Figure 2). In summary, long-term administration of compound 1 (LXF-32) of the present invention could significantly improve the liver function of TAA-induced hepatic fibrosis rats, down regulate the expression of a-SMA and Collal mRNA, reduce the deposition of collagen in the liver, and have a certain alleviating effect on liver fibrosis. 2) Pharmacodynamic evaluation of compound 8 (LXF-116) on CCL4-induced hepatic fibrosis model mice In this experiment, CCL4 induced hepatic fibrosis model mice were used to investigate the effect of long-term oral administration of compound 8 on hepatic fibrosis in the model mice. Experimental method: Male C57BL/6j mice were injected intraperitoneally with 2 mL/kg, 10% CCl4 (dissolved in olive oil) three times a week to induce liver fibrosis model. Two weeks after the model was made, the blood was taken from the retro-ocular venous plexus of the mice to detect serum ALT, AST, TBA and LDH indicators. According to ALT, AST, TBA, LDH, body weight and other indicators, the mice were randomly divided into 5 groups. There are 10 animals in each group, namely the model control group (Vehicle), low-dose compound 8 group (6 mg/kg), high-dose compound 8 group (20 mg/kg), low-dose positive compound OCA group (6 mg/kg), high-dose OCA group (20 mg/kg), etc., orally administered by gavage, once a day. During the administration period, the animals' food intake and body weight were monitored. After 3 weeks of administration, the blood was taken from the retro-ocular venous plexus of the mice to detect serum ALT, AST, TBA and LDH indicators. After 6 weeks of administration, the blood was taken from the retro-ocular venous plexus and the mice were dislocated and sacrificed. The livers were taken out and weighed. Part of the liver was fixed with 4% paraformaldehyde, and part of the liver was frozen at -80°C. During the whole experiment, another 10 mice in the same cage were intraperitoneally injected with the same volume of olive oil as the system normal control group (WT). This experiment detected indicators such as the levels of liver function indicators ALT, AST, TBA, LDH in serum, the expression of a-SMA and Collal gene levels in the liver, and the pathological changes of the liver (Sirius scarlet stain), etc., thereby reflecting whether the compound has the effect of relieving liver fibrosis.
The research results showed that the high-dose compound 8 group and low-dose compound 8 group of the present invention significantly reduced the levels of ALT, AST and TBA in serum after 6 weeks of administration, and had little effect on LDH; the high dose positive compound OCA group significantly reduced the levels of ALT, AST and TBA in serum and the low-dose group only had a lowering effect on TBA; the low-dose compound 8 group had a slightly better effect than the low-dose OCA group (Figure 3). The high-dose compound 8 group significantly down-regulated the expression of a-SMA in the liver, and down-regulated the expression of collal in the liver (Figure 4); in the quantitative analysis of liver pathological sections stained with Sirius scarlet, both the high-dose compound 8 group and low-dose compound 8 group significantly reduced the collagen content in the liver, and the effect of low-dose compound 8 group was slightly better than that of the low-dose OCA group (Figure 5). In summary, long-term administration of compound 8 (LXF-116) of the present invention could significantly improve the liver function of CCl4-induced hepatic fibrosis mice, down regulate the expression of a-SMA and Collal mRNA, reduce the deposition of collagen in the liver, and hava a certain alleviating effect on liver fibrosis
All documents mentioned in the present invention are cited as references in this application, just as each document is individually cited as a reference. In addition, it should be understood that after reading the above teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.
Reference to any prior art in the specification is not an acknowledgement or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be combined with any other piece of prior art by a skilled person in the art.
Claims (1)
- Claims 1. A compound represented by general formula I, or enantiomer, diastereomer, tautomer, racemate, solvate, or pharmaceutically acceptable salt thereof,0 R2 N H 1 QA NR R14 R12 R13wherein: R 1 1, R 12 , R 13 , R 14 and R 1 5 are each independently selected from: hydrogen, halogen, halogenated C1-6 alkyl, halogenated C1-C6 alkoxy, or C1-C6 alkyl; R 2 is selected from: phenyl, C-C6 alkyl or C3-C6 cycloalkyl;Q is selected from: I, , or /,wherein N is attached to A; A is a phenyl or pyridyl; and the phenyl or pyridyl is unsubstituted or substituted by one, two or three substituents selected from the group consisting of: halogen, C-C6 alkyl, and halogenated C1-6 alkyl; X is 0 or S.14 2. The compound of claim 1, wherein R, R 1 2, R1 3 ,R and R1 5 are each independently selected from: hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, or trifluoromethoxy.3. The compound as claimed in claim 1, wherein: R1 1 , and R15 are each independently selected from: hydrogen, chlorine, bromine, trifluoromethyl, or trifluoromethoxy; and R 12 , R 1 3, and R 14 are hydrogen.4. The compound of claim 1, wherein R 2 is selected from: phenyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl or cyclopentyl.5. The compound of claim 1, wherein Q is Ywherein N is attached to A.6. The compound of claim 1, wherein Xis 0.7. The compound of claim 1, wherein Ais aphenyl or pyridyl; and the phenyl or pyridyl is unsubstituted or substituted by one or two substituents selected from the group consisting of. fluorine, chlorine, bromine, and Cl-C4 alkyl.8. The compound of claim 1, wherein Ais selected from: , t, FFor F9. The compound of claim 1, wherein the compound is:'\ 0 NH 9\ 0 - N N N NN- N. C1 C1 ci ci / 0 N1H HN- \ CI112 30 N- 0 -0~ _ N / N~c -40 60 0 0 NN N~C1 KC HN-k CF 3 '/ ' OCF3 -' 40 -07 8 90 N.. C -) 0 0 NN N N 0 N/ -'CN/ N N,100 IHN-k HN-+ 11 1200 0 CN N ~ 0- N0-,N NN' 0 N NN NI HN4 ~ N N HN-+ 00 0 13 14 15N FP 0FP 0 F N N N, N, N HN4 C F o4 HN4 N16 17 18C1 ,N14 CF3W 'N HN- ' HN-4 - S -~020 210N 0 'N ~~ ~ HN-N NN/' C3 /' CF3 0N4 22 23 24 0' 0 FN 'N0'CF 3 0N CF 3/ '0 F 0N OCF3 / 'N' HN-{ 25 026 02700 NF 0N F O' 0 C F ' CF 3 0 'NF 0CF, 0N4 HN4 IN HN4 28 F2903N N N NN K~ N / N NF FHN-4 'NN 0 N3 31 0 320330No0, F a-1'Fi I NNN \1 ~ NN \/F ,N 0 F NF N- F C/1a'NH ' 3 OF HN-\k HN- IN 34 0 36F F~f 0-7 k,/N 'N OCF2 N N4 0FF HN- 4 'N CF HN-' F2 3738 40 1 39 HN 00-- NP . N 0-I\ N_ N- (-/' \/ 'N , k\ 'OCF 2H ' N4 'NHN40 HN-+ 40 41 0 or 42 H410. A method for preparing the compound according to claim 1, wherein the method comprises the following steps:0R2 0R2 0 g2O-Q-A O-Q-A N H CN N N O A N RR 15 Q R R H2 N N15 14R11 N-' R12 R14 R12 R144R R13 R 13 R12 Vil Vill R13(a') reacting a compound represented by general formula VII with hydroxylamine hydrochloride to produce a compound represented by general formula VIII; and (b') reacting the compound represented by the general formula VIII under the action of phosgene, triphosgene, carbonyldiimidazole or thiocarbonyldiimidazole to produce the compound represented by the general formula I, wherein, X, R2 , Q, A, R, R1 2 , R, R 4 and R are defined as in claim 1.11. The method of claim 10, wherein the compound represented by the general formula VII is prepared by the following steps:OH O R2 0/\0 NiI COOMe Br R15 R R15 b R R 15 C 1 5 a R"- RR1 12 R 14 R 124 R 14 13R13 R12 R 1R RR RR|| ||| IV V 2 R 2 R O O-Q-A, ONQ 0 &~ ~ , OCN Rd R R15 d R11 R 15 e12 WR4 R12 13 R14 .R R R1 Vil VI a) reacting substituted benzaldehyde compound represented by general formula II as starting materials with hydroxylamine hydrochloride to obtain an intermediate and then chlorinating the intermediate with N-chlorosuccinimide (NCS) to produce a compound represented by general formula III; b) reacting the compound represented by the general formula III with 3-oxopropionate to obtain a compound represented by the general formula IV; c) reducing the ester in the compound represented by formula IV to produce alcohol, and then brominating to produce a compound represented by V; d) reacting the compound represented by general formula V with Q-OH to produce a compound represented by general formula VI; e) coupling the compound represented by general formula VI with Br-A-CN under the catalysis of copper or palladium to obtain the compound represented by general formula VII, or prepared by the following steps: R2 R2 O Br O-Q-A, NBrCN RR15Q'OH + FA'CN HO-Q-A'CN R 15 + R g R1 13 14 R12 R 14 R 13 IX R V VIIf) reacting Q-OH with F-A-CN to generate a compound represented by general formula IX; g) reacting a compound represented by the general formula V with the compound represented by the general formula IX to produce the compound represented by the general formula VII, in each formula, R 2 , Q, A, R, R 1 2 , R 13 , R 14 and R 1 5 are defined as in claim 1.12. A pharmaceutical composition comprising the compound represented by the general formula I of claim 1, or the enantiomer, diastereomer, tautomer, racemate, solvate, or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.13. Use of the compound represented by the general formula I of claim 1, or the enantiomer, diastereomer, tautomer, racemate, solvate, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 12: (a) as an FXR agonist; (b) in the manufacture of a medicament for the treatment of FXR-related diseases; (c) to reduce the levels of ALP, ALT, AST and TBA in serum; (d) to reduce the amount of hydroxyproline in liver tissue; (e) to down-regulate the expression of a-SMA and Collal mRNA in liver tissue; or (f) to reduce the content of collagen in the liver.14. The use of claim 13, wherein the FXR-related disease is selected from: non-alcoholic fatty liver, primary biliary cirrhosis, primary sclerosing cholangitis, gallstone, non-alcoholic liver cirrhosis, liver fibrosis, cholestatic liver disease, hyperlipidemia, hypercholesterolemia, or diabetes.15. A method for treating the FXR-related disease, the method comprising administering an effective amount of the compound represented by the general formula I of claim 1, or the enantiomer, diastereomer, tautomer, racemate, solvate, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 12, to a subject in need thereof.16. Use of the compound represented by the general formula I of claim 1, or the enantiomer, diastereomer, tautomer, racemate, solvate, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 12, in the manufacture of a medicament for the treatment of an FXR-related disease.17. The method of claim 15 or the use of claim 16, wherein the FXR-related disease is selected from: non-alcoholic fatty liver, primary biliary cirrhosis, primary sclerosing cholangitis, gallstone, non-alcoholic liver cirrhosis, liver fibrosis, cholestatic liver disease, hyperlipidemia, hypercholesterolemia, or diabetes.model control group OCA 20mg/kg P.O qdphosphatase content Serum alkaline LXF-32 20mg/kg P.O qd normal control group(U/L)Pre- administration Time after administration Hydroxyproline content in livermodel control group OCA 20mg/kg P.O qd (μg/mg liver)LXF-32 20mg/kg P.O qd normal control groupmodel control group Col1α1 gene expression (fold of model group)OCA 20mg/kg P.O qd LXF-32 20mg/kg P.O qd normal control group expression (fold of model group) α-smooth muscle actin genemodel control group OCA 20mg/kg P.O qd LXF-32 20mg/kg P.O qd normal control groupFigure 1-1/4- normal control group model control group stained with Sirius scarlet (%) model control group Area ratio of collagenOCA 20mg/kg P.O qd LXF-32 20mg/kg P.O qd normal control groupFigure 2-2/4-Serum alanine aminotransferase model control group LXF-116 (6mg/kg) LXF-116 (20mg/kg)content (U/L) OCA (6mg/kg) OCA (20mg/kg) normal control groupPre- administration Time after administration aminotransferase contentmodel control group LXF-116 (6mg/kg) Serum aspartateLXF-116 (20mg/kg) OCA (6mg/kg) OCA (20mg/kg) normal control groupPre- administration Time after administration model control group Total bile acid contentLXF-116 (6mg/kg) LXF-116 (20mg/kg) in serumOCA (6mg/kg) OCA (20mg/kg) normal control groupPre- administration Time after administration model control group LXF-116 (6mg/kg) dehydrogenase contentLXF-116 (20mg/kg) OCA (6mg/kg) Serum lactateOCA (20mg/kg) normal control groupPre- administrationTime after administration Figure 3-3/4- model control groupCol1α1 gene expression (fold of model group) LXF-116 (6mg/kg) LXF-116 (20mg/kg) OCA (6mg/kg) OCA (20mg/kg) normal control group expression (fold of model group)model control group α-smooth muscle actin geneLXF-116 (6mg/kg) LXF-116 (20mg/kg) OCA (6mg/kg) OCA (20mg/kg) normal control groupFigure 4model control groupnormal control groupmodel control group stained with Sirius scarlet Area ratio of collagenLXF-116 (6mg/kg) LXF-116 (20mg/kg) OCA (6mg/kg) OCA (20mg/kg) normal control groupFigure 5 -4/4-
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910319757.X | 2019-04-19 | ||
CN201910319757 | 2019-04-19 | ||
CN201910969552.6A CN111825667B (en) | 2019-04-19 | 2019-10-12 | FXR small molecule agonist and preparation method and application thereof |
CN201910969552.6 | 2019-10-12 | ||
PCT/CN2020/085713 WO2020211872A1 (en) | 2019-04-19 | 2020-04-20 | Fxr small molecule agonist and preparation method therefor and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2020257379A1 AU2020257379A1 (en) | 2021-11-18 |
AU2020257379B2 true AU2020257379B2 (en) | 2022-09-29 |
Family
ID=72912098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020257379A Active AU2020257379B2 (en) | 2019-04-19 | 2020-04-20 | FXR small molecule agonist and preparation method therefor and use thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN111825667B (en) |
AU (1) | AU2020257379B2 (en) |
CA (1) | CA3137198C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112812114B (en) * | 2019-11-15 | 2024-05-28 | 四川科伦博泰生物医药股份有限公司 | Isoxazole derivative, pharmaceutical composition containing same, preparation method and application thereof |
CN114315830A (en) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | FXR small molecule agonist and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108017636A (en) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | Nitrogen-containing heterocycle compound as FXR conditioning agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5301286B2 (en) * | 2006-02-03 | 2013-09-25 | イーライ リリー アンド カンパニー | Compounds and methods for modulating FX receptors |
CU24152B1 (en) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
US10080742B2 (en) * | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
CN110177783B (en) * | 2016-08-23 | 2023-06-06 | 阿德利克斯股份有限公司 | Hormone receptor modulators for the treatment of metabolic conditions and disorders |
-
2019
- 2019-10-12 CN CN201910969552.6A patent/CN111825667B/en active Active
-
2020
- 2020-04-20 AU AU2020257379A patent/AU2020257379B2/en active Active
- 2020-04-20 CA CA3137198A patent/CA3137198C/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108017636A (en) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | Nitrogen-containing heterocycle compound as FXR conditioning agents |
Also Published As
Publication number | Publication date |
---|---|
CN111825667A (en) | 2020-10-27 |
CA3137198C (en) | 2023-07-11 |
CA3137198A1 (en) | 2020-10-22 |
AU2020257379A1 (en) | 2021-11-18 |
CN111825667B (en) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3957640A1 (en) | Fxr small molecule agonist and preparation method therefor and use thereof | |
IL292943A (en) | Glp-1 receptor agonist and use thereof | |
WO2020034988A1 (en) | Salt of apoptosis signal-regulating kinase 1 inhibitor and crystal form thereof | |
KR20220063192A (en) | BRD9 bifunctional disintegrant and method of use thereof | |
CA2985542A1 (en) | Triazole agonists of the apj receptor | |
AU2020257379B2 (en) | FXR small molecule agonist and preparation method therefor and use thereof | |
CA2694724C (en) | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | |
JP2008535782A (en) | Pyrrolidine and piperidine acetylene derivatives for use as mGluR5 antagonists | |
WO2017006953A1 (en) | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | |
DK2599774T3 (en) | DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands | |
EP4301752A1 (en) | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | |
CZ283993A3 (en) | Phenoxy- and phenoxyalkyl piperidines as antiviral active substances | |
KR20210059584A (en) | Glp-1 receptor agonist and use thereof | |
WO2021252555A1 (en) | Collagen 1 translation inhibitors and methods of use thereof | |
KR101524208B1 (en) | Benzoin oxazole derivatives, preparation method thereof and pharmaceutical compositions that contain them | |
EP4223757A1 (en) | Fxr small-molecule agonist, and preparation method therefor and use thereof | |
KR20230104614A (en) | Acetamido-phenylbenzamide derivatives and methods of use thereof | |
WO2023284159A1 (en) | Compound containing sulfamide structure, and preparation method therefor and application thereof, and pharmaceutical composition and application | |
CN115380036A (en) | SSTR5 antagonists | |
EA046249B1 (en) | LOW MOLECULAR FXR AGONISTS, THEIR PRODUCTION METHOD AND APPLICATION | |
WO2022012534A1 (en) | Nitrogen-containing heterocyclic compound, pharmaceutical composition, and applications | |
WO2021233427A1 (en) | Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof | |
WO2024052692A1 (en) | Novel compounds as ck2 inhibitors | |
WO2023175185A1 (en) | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer | |
TW202146403A (en) | Nitrogen-containing heterocyclic compound, preparation method, pharmaceutical composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: VAN ANDEL RESEARCH INSTITUTE Free format text: FORMER OWNER(S): SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Free format text: FORMER OWNER(S): SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |